Review Article

Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review

Meng-Ying Cui, Xing Yi, Zhen-Zhen Cao, Dan-Xia Zhu, and Jun Wu

Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China

Correspondence should be addressed to Dan-Xia Zhu; zhudanxia66@163.com and Jun Wu; wujun1378@163.com

Meng-Ying Cui and Xing Yi contributed equally to this work.

Received 28 March 2022; Revised 10 July 2022; Accepted 13 July 2022; Published 5 September 2022

Academic Editor: Achuthan Chathrattil Raghavamenon

Copyright © 2022 Meng-Ying Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Esophageal cancer is of high importance to occurrence, development, and treatment resistance. As evidenced by recent studies, pathways (e.g., Wnt/β-catenin, AMPK, and Hippo) are critical to the proliferation, differentiation, and self-renewal of esophageal cancer. In addition, the above pathways play a certain role in regulating esophageal cancer and act as potential therapeutic targets.

Over the past few years, the function of lipid metabolism in controlling tumor cells and immune cells has aroused extensive attention. It has been reported that there are intricate interactions between lipid metabolism reprogramming between immune and esophageal cancer cells, whereas molecular mechanisms should be studied in depth. Immune cells have been commonly recognized as a vital player in the esophageal cancer microenvironment, having complex crosstalk with cancer cells. It is increasingly evidenced that the function of immune cells in the tumor microenvironment (TME) is significantly correlated with abnormal lipid metabolism. In this review, the latest findings in lipid metabolism reprogramming in TME are summarized, and the above findings are linked to esophageal cancer progression. Aberrant lipid metabolism and associated signaling pathways are likely to serve as a novel strategy to treat esophageal cancer through lipid metabolism reprogramming.

1. Introduction

The incidence of esophageal cancer (EC) ranks seventh among all malignant tumors, and there are significant geographical differences in the incidence of esophageal cancer, with rare incidence in developed nations (e.g., Europe and the United States), as indicated by the epidemiological statistics in 2018. The incidence of EC has been extremely high in developing nations [1]. Esophageal cancer primarily has two pathological types, including esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). Squamous cell carcinoma has been more commonly diagnosed in males, with a relationship to smoking and alcohol abuse, while adenocarcinoma is correlated with Barrett’s esophagus, gastroesophageal reflux, and hiatal hernia [2, 3]. EAC has been common in developed nations, while ESCC is more commonly detected in Asia, Africa, and other developing nations. In addition, China is a high incidence area of esophageal cancer, and there is a significant gender difference in the incidence of esophageal cancer, with male incidence significantly higher than female incidence [4]. The surgical removal of a lesion is considered a highly effective way to cure esophageal cancer, whereas the early symptoms are not typical. Most patients are diagnosed with the disease at the middle and advanced stages, thus missing the opportunity for surgical treatment. Accordingly, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and other comprehensive therapies for the treatment of esophageal cancer are found to play a major role, whereas the overall survival rate of esophageal cancer remains not ideal [5]. As indicated by the latest investigation, significant changes have occurred in the metabolism of a wide range of nutrients in tumor cells, among which lipid metabolism reprogramming has aroused rising attention.
since it can promote tumorigenesis and metastasis. As the regulatory mechanisms of lipid metabolism have not been comprehensively clarified, the application of targeted lipid metabolism in tumor treatment has emerged. Furthermore, tumor cells interact with immune cells, thus having an effect on the microenvironment of lipid metabolism. At present, esophageal cancer arises from the action of a defective factor (e.g., a diet, an environment, and a gene), thus leading to body metabolism and the change of cells [6]. As confirmed by existing studies, esophageal cancer are multigene mutations in somatic cell levels, which are essentially correlated with the genetic susceptibility of biological individuals. Moreover, cancer cells are gradually produced in an external environment (e.g., diets, nutrition, and viruses). Subsequently, numerous esophageal cancer-free genes and susceptibility genes have been discovered, and most of them are concentrated in association, lipid metabolism, and vitamin synthesis-related gene regions [7]. Under physiological conditions, saccharides, lipids, and amino acid metabolism lay a basis for the body’s normal life activities. However, in patients suffering from esophageal cancer, the amount of energy demand increases since tumor cells are rapidly proliferated, thus resulting in the metabolism of tumor tissue and normal tissue, which is significantly different from [8]. Existing studies have found key enzymes that play a certain role in lipid metabolism, which can increase the incidence of esophageal cancer and have a certain effect on cancer [9, 10]. According to epidemiological studies, the risk of malignant tumors in obese populations includes an elevated risk of esophageal squamous cell, which reveals that fatty acid metabolism is critical to the development of tumors [10–12]. Fatty acids have been found as the main energy source of mammals for the normal growth and metabolism of cells. Fatty acids can be broken down into carbon dioxide and water in vivo, and a considerable amount of energy is released in the form of ATP and exploited by the organism [13]. However, the process of fatty acid oxidation of esophageal cancer and the synthesis of endogenous fatty acids remain unclear. The specific mechanisms of the above fatty acid metabolism, which play a certain role in regulating esophageal squamous cell carcinoma, have been rarely known. Besides, the role played by lipid metabolism in regulating immune cells has aroused extensive attention. Furthermore, immunocytes are critical to an esophageal cancer microenvironment and exhibit complex crosstalk with cancer cells. Thus, the key pathway to the identification of esophageal cancer’s metabolism can significantly explore the occurrence of the esophagus, and it can present novel insights into the diagnosis and treatment of esophageal cancer. It is desirable to develop ESCC new biological markers and immune environment drug resistance mechanisms and lay a theoretical basis for targeted treatment.

2. Introduction to Esophageal Cancer

Esophageal cancer refers to the eighth most common type of cancer worldwide and the sixth leading cause of cancer death. It is characterized by high mortality, poor prognosis at diagnosis, and geographical variation. This type of cancer includes two primary malignancies, including ESCC and EAC. While ESCC remains the most common type worldwide, EAC is rapidly becoming the most common type in developed nations. Adenocarcinoma and squamous cell carcinoma are recognized as two different tumor types. ESCC is significantly correlated with the life and environmental factors (e.g., drinking and smoking, hot drinking, as well as taking nitrosamines). In addition, the deficiency of micronutrients (e.g., vitamin C, vitamin E, and folic acid) is correlated with the development of squamous cell carcinoma of the esophagus [6]. The above factors may change the genomic pattern of genes and epigenetics. On the whole, the progression of ESCC consists of five stages, that is, simple epithelial hyperplasia, atypical hyperplasia, preinvasion cancer, invasive carcinoma, and metastatic carcinoma. Stunting has been found as a crucial step in the development of ESCC. As indicated by histological analysis, atypical hyperplasia is characterized by basal cell hyperplasia with irregular epithelial stratification and increased normal and abnormal mitosis. Moreover, atypical hyperplasia is manifested as enlarged nucleoli, keratosis of individual cells, loss or decrease in cell cohesion, and loss of cell polarity before malignant transformation [14].

Barrett’s esophagus (BE), characterized by the presence of a columnar mucosa of the esophagus, is considered a complication of gastroesophageal reflux disease (GERD) and a precancerous lesion to EAC [15, 16]. Over the past few years, the incidence of EAC has increased rapidly worldwide, especially in developed nations, which probably arises from an increase in obesity and a decrease in Helicobacter pylori infection [17]. For esophageal adenocarcinoma, risk factors include BE, gastroesophageal reflux disease, obesity, and tobacco consumption. The development of BE has been the only known risk factor of EAC. The EAC appears to emerge via a metaplasia-atypical hyperplasia-cancer sequence in which Barrett’s metaplasia can develop into low-grade atypical hyperplasia, into high-grade atypical hyperplasia, and finally into intramucosal carcinoma and invasive carcinoma [14]. As revealed by the latest research, ESCC and EAC have different cell sources. It is noteworthy that some of the above models suggest that the malignant transformation of stem cells/progenitor cells leads to the sequential development of tumors [18–20].

Lipid metabolism plays a vital role in the occurrence and development of tumors, either esophageal squamous cell carcinoma or esophageal adenocarcinoma. As indicated by the findings of Shawn A, dietary intake of fish/shellfish, particularly nonfried and high N-3 fatty acids and long-chain N-3 polyunsaturated fatty acids might increase the risk of developing esophageal adenocarcinoma due to its relatively high N-3 unsaturated fatty acid content. Long-chain N-3 PUFA would be the precursors to anti-inflammatory lipid mediators that inhibit angiogenesis and induce apoptosis. As opposed to the above finding, arachidonic acid of long-chain N-6 PUFA would be a precursor to pro-inflammatory lipid mediators [21, 22]. As demonstrated by Odera et al., NRF2/ACSS2 axis and ethanol exposure could facilitate OXPHOS and lipid synthesis in ESCC cells,
2.1. The Involvement of Dietary Fats in the Onset of Esophageal Cancer. Glycerol and fatty acids, which are substances including polyunsaturated fatty acids (PUFAs), monounsaturated fatty acids (MUFAs), and saturated fatty acids (SFAs), compensate for the triglyceride that makes up natural dietary fat [24]. On the one hand, fatty acids can promote cancer aggressiveness, but on the other hand, they have been identified as potential targets for anticancer metabolic therapy [25]. To the best of our knowledge, food consumption and nutritional status are being acknowledged as important factors in the treatment of esophageal cancer. Excess adipose tissue resulting from high-fat intake releases more tumorigenic adipokines. Leptin adipokines, for instance, have been demonstrated to promote the proliferation and survival of EAC cell lines in vitro [26]. Ma et al.’s study showed that a high-fat diet can boost the activity of peroxisome proliferator-activated receptor gamma (PPARG) in gastroesophageal cells, and upregulation of PPARG can increase the de novo synthesis of fatty acids, phospholipids, and sphingolipids and promote the occurrence and development of esophageal adenocarcinoma [27]. Esophageal adenocarcinoma (EAC) and esophagogastric junction adenocarcinoma (EGJAC) have been reported to be positively related to meat consumption and high-fat diets [28]. At the same time, dietary fat and specific intake of SFAs and PUFAs were associated with an increased risk of esophageal adenocarcinoma, while substantially inversely linked with esophageal carcinoma squamous cell type [29]. After further stratification by lifestyle exposure factors, Hu et al. found that even-chain unsaturated fatty acid (EC-UFA) patterns were associated with an increased ESCC risk, whereas the N-3 long-chain polyunsaturated fatty acid (N-3 LC-PUFA) pattern intake was associated with a reduced risk of ESCC. However, no significant associations were observed with MLC-SFA or SFA patterns among the study subjects [30].

2.2. Reprogramming of Lipid Metabolism in Esophageal Cancer. In malignancies, the production of endogenous fats and the consumption of exogenous lipids can satisfy the high demand of cancer cells for lipids. They are highly coordinated and finely controlled molecular procedures in which the PI3K/Akt/mTORC1 pathway activates the sterol regulatory element-binding protein (SREBPs) and changes the nutrition status of cancer cells. For instance, SREBPs are capable of regulating the synthesis of cholesterol and fatty acids and the expressions of key enzymes correlated with the synthesis. CD36, as a long-chain fatty acid receptor, can express exogenous fatty acid uptake, not just as an energy source, but also enhance intrusiveness in ESCC [31]. ACBP (Acetyl-CoA-binding protein) refers to the middle-long chain of the intracellular acetyl-CoA carrier protein that transports fatty acid in mitochondria for β-oxidation. ACBP has three types, including 1-acetyl-CoA-binding protein (1-ACBP), B-acetyl-CoA-binding protein (B-ACBP), and peripheral β-CoA-binding protein (PBR) [32]. It has been demonstrated that the three esophageal cancer genes increased significantly in the area of the malignant tissues of esophageal cancer. Furthermore, acetyl-CoA synthesis enzyme short-chain family member 2 (ACSS2) is capable of converting acetate into acetyl-CoA. The NRF2/ACSS2 axis will allow ENSC cells to exploit ethanol-derived acetate as their energy source. It can regulate downstream ethanol metabolism and metabolic reprogramming in ESCC, while inducing lipid synthesis and alcohol-related ESCC [23].

As indicated by recent experiments, the lack of fructose-1,6-biophosphatase (FBP1) was correlated with the active metabolism of fatty acids in vitro and facilitated the proliferation, migration, and invasion of ESCC cells. In addition, protein expression levels for fatty acid synthase (FASN), acetyl-CoA carboxylase 1 (ACC1), and sterol regulatory element-binding protein 1C (SREBP1C) were correlated with triglycerides, neutral lipids, and fatty acid metabolism, while increasing significantly due to FBP1 regulation [33]. FASN is highly present in the phenotypes of the intestinal mucus of BE. Exposure to low pH and low bile acid in the esophagus may result in the expression of FASN in BE. SREBP1 can foster proliferation and induce epithelial-to-interstitial transition by activating stearoyl-CoA desaturase 1 (SCD1)-induced Wnt/β-catenin signaling pathways with carcinogenic effects on ESCC [34]. Cholesterol synthesized using mevalonic acid is critical to maintain the physical properties of the membrane, cell signaling, and physiological activity. The axis of the PI3K/Akt/mTORC1 signal can contribute to the acquisition of characteristics similar to those of cancer stem cells in squamous cell lines of the esophagus. Moreover, sterol regulatory element-binding protein 2 (SREBP2) raised HMG-CoA synthase, while MVA increased significantly. Cholesterol is catalyzed by acyl coenzyme by 3-hydroxy-3-methylglutaryl (HMG)-CoA synthase and hydroxy-3-methylglutaryl-CoA reductase (HMGCR) to synthesize mevalonic acid. Esophageal cancer cells overexpressing HMGCR could facilitate cell growth and migration and colony formation [35]. The specific process is shown in Figure 1 and Tables 1–3.

2.3. Lipid Metabolism-Related Enzymes and Regulatory Factor Targets

2.3.1. ACSS2. Cancer cells are primarily dependent on acetate as a carbon source to synthesize fatty acids without oxygen-poor nutrients [98]. To be specific, acetic acid is catalyzed by ACSS2 to synthesize acetyl coenzyme A, which creates a key carbon source for cancer cells and overcomes oxidative stress and metabolism. ACSS2 refers to the only enzyme recycling acetate from desalination reactions to the cytoplasm and nucleus [36]. In a state of nutritional
deficiency and oxidative stress, ESCC induces continuous growth and resistance to chemotherapy via the ACSS2/AMP-activated protein kinase (AMPK)/proliferating cell nuclear antigen (PCNA) pathways. Ming et al. demonstrated the function of nutritional stress (NS)-mediated acetyl coenzyme. ACSS2 can accelerate the recurrence of esophageal cancer patients and induce cisplatin resistance [37]. Moreover, it may serve as a potential biomarker to identify high-risk esophageal cancer patients. Ye et al. proved that differences in acetate levels in EC serum are correlated with choline levels in esophageal tissue, thus showing an improvement in lipid metabolism required for cell membranesynthesis in tumor cells [99]. Alcohol is also a critical element in the development of esophageal squamous cell carcinoma. As indicated by the experiment of Odera et al., NRF2/ACSS2 axis mediated the metabolic effect of alcohol drinking on ESCC [23]. In brief, ACSS2 targets in patients with esophageal cancer may create superior survival benefits. The above strategy may be required to be further validated in future clinical studies of inhibitors for esophageal cancer-targeting lipid metabolism with large sample sizes.

2.3.2. ACC. Acetyl coenzyme refers to the second stage of fatty synthesis. It is an irreversible carboxylation to synthesize acetyl coenzyme A. ACC consists of two subtypes: ACC1 is locally cytoplasmic and synthesizes malonyl-CoA for the synthesis of fatty acids, while ACC2 is bound to the mitochondria’s outer membrane, largely present in the lipid oxidation tissue. On the whole, acetyl coenzyme A is a variant inhibitor of carnitine acyltransferase 1 (CPT1) that regulates FAO [100]. Arising from their positions in subcells differ, the above two subtypes have distinct metabolic functions. ACC1 largely plays a certain role in lipid synthesis, while ACC2 primarily inhibits lipid degradation [101]. ACC1 locally generates malonyl-CoA, thus contributing to fatty acid synthesis. ACC2 binds to mitochondrial outer membranes and produces malonyl-CoA, and its action as an inhibitor for CPT1 regulates fatty acid β-oxidation [102]. In esophageal cancer, FBP1 acts as the major catalytic fructose-1,6-biphosphonate to produce a fructose-6-phosphate reversible reaction. Still, it is a surprising finding that the low expression of FBP1 can significantly promote fatty acid metabolism-related FASN, ACC1, and SREBP1C expression levels and eventually facilitate ESCC cell

---

**Figure 1:** Overview of fatty acid metabolism in esophageal cancer cells. Lipid uptake can be achieved through multiple routes. ACLY, ATP citrate lyase; ACC, acetyl-CoA carboxylase; FASN, fatty acid synthase; SCD1, stearoyl-CoA desaturase 1; ACSS2, acetyl-CoA synthetase 2; ACS, acyl-CoA synthetases; CPT1, carnitine palmitoyl transferase 1; MAGL, monoacylglycerol lipase. TGs/CE, triglycerides/cholesteryl esters; TAG, triacylglycerol; FAs, fatty acids; FAO, fatty acid oxidation; LDLR, low-density lipoprotein receptor; HMG-CoA, hydroxy-3-methylglutaryl-CoA; HMGCR, hydroxy-3-methylglutaryl-CoA reductase; HMGCS, 3-hydroxy-3-methylglutaryl coenzyme A synthase; LDs, lipid droplets; SREBPs, sterol regulatory element-binding proteins.
| Markers | Cancer Type | Significance | Name | Marker for diagnosis or prognosis | Reference |
|---------|-------------|--------------|------|-----------------------------------|-----------|
| ACSS2   | ESCC        | ACSS2 can recycle acetate (including both protein and metabolite deacetylation reactions) to produce acetyl-CoA, which is a raw material for fatty acid and cholesterol synthesis [36]. | Lei et al. | The expression of ACSS2 is closely related to the prognosis of patients with ESCC. | [37] |
| ACC     | ESCC        | Acetyl-CoA carboxylase catalyzes the conversion of acetyl-CoA to malonyl-CoA. ACC promotes FA synthesis and the energy metabolism. Downregulation the expression of p-ACC is associated with tumor cell differentiation in ESCC. | Zhao et al. | | [50] |
| FASN    | ESCC, Barrett’s esophagus/OAC, ESCC/OAC | FASN is a key enzyme for lipid metabolism and is associated with tumor invasion and metastasis [38]. FASN expression was associated with the risk of malignancy progression. FASN promotes the development of esophageal squamous cell carcinoma. FAS has the potential to be oncogenic in EC. | Ishimura et al. Wang et al. Zhou et al. | | [39] [40] [41] |
| SCD1    | ESCC        | SCD1 appears to be a significant player in the development of tumor and may be a promising target for anticancer therapy [51]. | Zemanova et al. | Compared with healthy patients, both saturated and monounsaturated fatty acids were increased in esophageal cancer patients due to increased activity of SCD1 | [52] |
| ELOVL5  | ESCC        | ELOVL5 is a key enzyme for de novo synthesis of long-chain unsaturated fatty acids. | Zhao et al. | ELOVL5 is upregulated in EC and is associated with a poor prognosis in patients. | [53] |
| CD36    | ESCC        | CD36-driven lipid metabolic reprogramming and tumor development [54]. | Yoshida et al. | CD36 was associated with tumor invasion and metastasis in ESCC. | [31] |
| SREBP1  | ESCC        | SREBP1 may provide the potential for the diagnosis and treatment of ESCC. SREBP1 exerts oncogenic effects in ESCC by promoting proliferation and inducing epithelial-mesenchymal transition via the SCD1-induced activation of the Wnt/β-catenin signaling pathway. | Shao et al. Wang et al. | SREBP1 can be used as an independent prognostic marker for ESCC. SREBP1 contributes to the development of novel biomarkers and therapeutic targets for ESCC. | [55] [34] |
| SREBP2  | ESCC        | Sterol regulatory element-binding protein 2 (SREBP2), the master regulator for HMGCRCR, is upregulated in ESCC clinical samples. SREBP2 is closely related to ESCC tumorigenesis. | Zhong et al. | | [42] |
| CPT1A   | ESCC        | CPT1A acts as a key enzyme in fatty acid oxidation and regulates tumor energy metabolism. CPT1A is capable of potential biomarkers for the risk prediction for ESCC. | Shi et al. | | [46] |
| Markers                                      | Cancer Type | Significance                                                                 | Name            | Marker for diagnosis or prognosis                                                                 | Reference |
|----------------------------------------------|-------------|-------------------------------------------------------------------------------|-----------------|---------------------------------------------------------------------------------------------------|-----------|
| Carnitine                                    | EAC/ESCC    | Levels of octanoylcarnitine, lysoPC (16:1), and decanoylcarnitine are closely related to the effectiveness of ESCC treatment [44, 56] | Li et al.       | Carnitine is capable of potential biomarker for the risk prediction and early detection of ESCC. | [57]      |
| I-Carnitine/acylcarnitin                     | ESCC        | Levels of octanoylcarnitine, lysoPC (16:1), and decanoylcarnitine have been reported to be associated with the treatment effects and are identified as potential biomarkers. | Xu et al.       | Acylcarnitine is a potential biomarker of ESCC                                                    | [58]      |
| Octanoylcarnitine, lysoPC (16:1), and decanoylcarnitine | ESCC    | Levels of octanoylcarnitine, lysoPC (16:1), and decanoylcarnitine have been reported to be associated with the treatment effects and are identified as potential biomarkers. | Xu et al.       | Levels of octanoylcarnitine, lysoPC (16:1), and decanoylcarnitine have been reported to be associated with the treatment effects and are identified as potential biomarkers. | [59]      |
| LDs                                          | Barrett’s esophagus/OAC | Lipid droplets are dynamically active and control lipid homeostasis. | Carrossini et al. | LDs are increased along EAC evolution as a consequence of the exposure of the esophageal epithelium to the risk factors associated with BE and EAC. | [49]      |
| Cholesterol                                  | ESCC/OAC    | Cholesterol is a useful component of lipid rafts and controls various signaling pathway. | Zhu et al.      | Cholesterol can be used as a potential biomarker of EC.                                         | [43]      |
| LPCAT1                                       | ESCC        | LPCAT1 regulates SREBP1 and SREBP2-related signaling pathways in ESCC cells. | Tao et al.      | LPCAT1 may be a useful biomarker for ESCC diagnosis and prognosis.                              | [60]      |
| HMGCR                                        | ESCC        | 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is the rate-limiting enzyme in cholesterol biosynthesis. | Zhong et al.    | HMGCR may be an important therapeutic target for esophageal squamous cell carcinoma.            | [35]      |
| FABP1                                        | OAC         | Fatty acid-binding proteins (FABPs) are intracellular proteins that bind long-chain fatty acids (FA) and are related to immunometabolic diseases. | Srivastava et al. | FABP1 can clearly discriminate Barrett’s esophagus from columnar lined esophagus.              | [48]      |
| HNRNPA2B1                                    | ESCC/EAC (both) | HNRNPA2B1 upregulates ACLY and ACC1 and promotes ESCA progression. | Guo et al.      | HNRNPA2B1 can be a useful ESCA prognostic biomarker and therapeutic target.                     | [61]      |
| Long-chain fatty acids                       | ESCC        | De novo synthesis of strong fatty acids during esophageal cancer cell proliferation and metastasis leads to increased serum long-chain fatty acids. | Jin et al.      | Long-chain fatty acids are used as a metabolic sign of tumorigenesis and metastasis of ESCC.     | [45]      |
| Linoleic acid                                | ESCC        | Linoleic acid as a metabolite marker | Zhang et al.    | Linoleic acid is used to discriminate ESCC and ESD patients and provides helpful reference for clinicians. | [62]      |
| Phosphatidylcholines and choline kinase      | ESCC        | The key enzyme in the phosphatidylcholine metabolism pathway | Ma et al.       | Phosphatidylcholines may be used as novel biomarkers for ESCC.                                   | [63]      |
| Markers                  | Cancer Type            | Significance                                                                 | Name          | Marker for diagnosis or prognosis                                               | Reference |
|-------------------------|------------------------|-------------------------------------------------------------------------------|---------------|--------------------------------------------------------------------------------|-----------|
| PGE2                    | ESCC                   | Prostaglandin E2 (PGE2), an active lipid compound derived from arachidonic acid, regulates different stages of the immune response. | Kuo et al.   | EP2 expression became an independent factor of overall survival. EP2 overexpression is associated with worse prognosis and correlated positively with T status in ESCC. | [64]      |
| LPE and LPC             | Esophageal squamous dysplasia (ESD)/ESCC | Lysophosphatidylethanolamine (LPE) and lysophosphatidylcholine (LPC) serve as a new panel of plasma biomarkers to predict ESCC development. | Zhu et al.   | LPE and LPC demonstrated a good diagnostic value.                              | [8]       |
| FADS1                   | ESCC                   | Fatty acid desaturase 1 (FADS1), the rate-limiting enzyme, participates in the desaturation and elongation cascade of polyunsaturated fatty acids to generate long-chain PUFAs. | Du et al.     | FADS1 might be a valuable biomarker and potential therapeutic target for ESCC. | [65]      |
| Palmitoleic acid palmitaldehyde isobutyl decanoate | ESCC | A marker board consisting of palmitoleic acid, palmitaldehyde, and isobutyl caprate may be used as an innovative biomarker for the diagnosis and prognosis of ESCC. | Zhu et al.   | Palmitoleic acid, palmitaldehyde, and isobutyl decanoate are used as diagnostic biomarkers of ESCC patients. | [47]      |
| Apolipoprotein A1       | ESCC                   | A major component of HDL.                                                    | Wang et al.   | Apolipoprotein A1 is associated with ESCC patient survival rate.               | [66]      |
| CRABP2                  | ESCC                   | The CRABP2 gene, a member of the retinoic acid-binding protein family, binds to retinoic acid in the cytoplasm, transports it, and activates the transcription of related genes. | Li et al.     | CRABP2 as a suppressor factor is associated with ESCC prognosis.               | [67]      |
| Compounds | Function | Reference | Clinical trials/inhibitors |
|-----------|----------|-----------|---------------------------|
| ACSS2 | Acetyl-CoA synthetase 2 (ACSS2) converts acetate to acetyl-CoA to participate in lipid metabolism and promote whole-body fat storage and utilization. | [71] | Amide-substituted condensed pyridine derivatives [72] tetrazoles [73] |
| ACC | Acetyl-CoA carboxylases (ACC) are rate-limiting enzymes in de novo fatty acid synthesis, catalyzing acetyl-CoA to form malonyl-CoA. | [74] | Sorafen A piperidinyl derived analogs spiropiperidine derived compounds TOFA ND-630-related compounds Aryl ether derived analogs [68] Haloxyfop sethoxydim Andrimid moiramide B ESP-55016 S-2E CP-640186 [69] |
| SCDs | Stearoyl-CoA desaturase 1 (SCD1), the enzyme that converts saturated fatty acids to Δ9-monounsaturated fatty acids. | [51] | A939572 MF-438 CVT-11127 CVT-12012 CAY10566 CAY10566 T-3764518 BZ36 SSI-4 SW208108 SW203668 [51] |
| CPT1 | Carnitine palmitoyltransferase I (CPTI) as the key rate-limiting enzyme of FAO facilitates tumor development. | [75] | Etomoxir STI326 [75] |
| HMGCR | The third step in the mevalonate pathway, catalyzed by HMGCR, that has been involved in the tumorigenesis of ESCC. | [35, 76] | Statins [77] |
| FABP1 | Fatty acid-binding proteins (FABPs) are intracellular proteins that ingest exogenous long-chain fatty acids (FA) into cells, thereby promoting tumor growth and utilization. | [48, 78] | Niacin derivatives, quinoxaline derivatives, aryl-quinoline derivatives, bicyclicpyridine derivatives, urea derivatives, 1,2,5-dimethyl-[1,2,4]triazolo[1,5-α]pyrimidin-7 (4H)-ones N-(thiophen-2-yl)acetamides [79] |
| CD36 | CD36 is a key carrier mediating exogenous uptake of fatty acids and a regulator of ESCC energy sources. | [31, 54] | ABT-510 CVX-O45 ABT-526 ABT-898 CVX-022 3TSR TAX2 ELK-SAHPS [54] |
| LDL | Low-density lipoprotein is a convenient biomarker and is strongly associated with poor prognosis in esophageal squamous cell carcinoma. | [70] | Anti-PCSK9 antibodies (evolocumab and alirocumab) [80] |
| Target                                      | Agent                          | Type   | Mechanism                                                                                                                                                                                                 | Trial ID or reference |
|---------------------------------------------|--------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Mitochondrial complex I and metformin ACC    | Metformin                      | ESCC   | Metformin can be used as an alternative therapy for chemotherapy- and radiotherapy-refractory esophageal squamous cell carcinoma by inducing cell apoptosis. Metformin inhibited the growth and metastasis of ESCC. | [83]                  |
| Metformin with gemcitabine                  |                                | OSCC   | Metformin inhibits the growth and metastasis of ESCC.                                                                                                                                                    | [84]                  |
| Metformin with cisplatin                    |                                | ESCC   | Metformin combined with chemotherapy can reverse cisplatin resistance by reducing intracellular glutathione levels.                                                                                       | [85]                  |
| Natural alkaloid                            | Berberine                      | ESCC   | By targeting and blocking miR-212, berberine effectively inhibits the invasion and metastasis of ESCC. miR-18b-5p regulates de novo lipid synthesis by regulating FASN, ACC1, and SREBP1C and promotes ESCC tumorigenesis and progression. | [86]                  |
| miR-18b-5p                                  |                                | ESCC   |                                                                                                                                             |                       |
| Nonsteroidal anti-inflammatory drugs (NSAIDs) | Acetylsalicylic acid (aspirin) | ESCC   | Aspirin enhances the therapeutic efficacy of cisplatin in ESCC. The combination of aspirin and statin is cost-effective in patients at high risk for progression to esophageal adenocarcinoma.                  | [87]                  |
| Aspirin + statins                           |                                | OSCC   |                                                                                                                                             | [88]                  |
| HMG-CoA reductase (HMGCR)                   | Statins (e.g., simvastatin and atorvastatin) | OSCC   | The use of statins is associated with a significantly lower incidence of OSCC. Atorvastatin inhibits ESCC tumor growth in a PDX model by inhibiting the cAMP and Rap1 signaling pathways. | [89]                  |
| HMG-CoA reductase (HMGCR)                   | Statins (e.g., simvastatin and atorvastatin) | ESCC   |                                                                                                                                             |                       |
| Part of carnitine palmitoyltransferase 1 (CPT1) | Carnitine/organic cation transporter novel 2 + Oxaliplatin | ESCC   | High expression of OCTN2 promotes the accumulation and cytotoxic activity of oxaliplatin in patients with esophageal cancer, resulting in a reduced risk of recurrence and prolonged survival in EC patients. | [90]                  |
| Target | Agent | Type | Mechanism | Trial ID or reference |
|--------|-------|------|-----------|-----------------------|
| Fatty acid synthase (FASN) | Orlistat (a pancreatic lipase inhibitor developed for obesity treatment), C75, a first-generation synthetic small-molecule inhibitor of FAS, C93, a second-generation small-molecular inhibitor with increased specificity. Previous efforts to treat xenograft cancers with C75 | Squamous carcinoma and adenocarcinoma of the esophagus, as well as cases of Barrett’s esophagus with varying levels of dysplasia | FAS is expressed at very high levels in esophageal cancer and growth of these cancers can be inhibited by C93. C75 inhibited OSCC proliferation | [39, 81] |
| Diferuloylmethane | Curcumin | ESCC/OSCC | Curcumin has influences on FAS activity, FAO, and desaturation system. Curcumin may inhibit the proliferation and colony formation of EC according to dose and time. | [93, 94] |
| Sterol regulatory element-binding proteins (SREBPs) | Fatostatin (4-hydroxytamoxifen, an active metabolite of tamoxifen) | ESCC | Fatostatin significantly inhibited tumorigenesis by downregulating SREBP1 and EMT markers. | [82] |
| Estrogen receptor (ER) receptor | Natural estrogen (17b-estradiol) selective ER modulators (SERM) tamoxifen and raloxifene | OSCC and Barrett’s esophagus | Tamoxifen and raloxifene act as agonists of ER signaling, producing pro-apoptotic and growth-inhibitory effects. | [95] |
| SQLE inhibitor | siRNA | ESCC | The siRNA significantly inhibited the proliferation and invasion of esophageal cancer cells by regulating the expression of cell cycle and EMT-related proteins. | [96, 97] |
proliferation, migration, and invasion. Whether an effect on ESCC progression is exerted possibly by affecting fatty acid metabolism should be investigated in depth [4]. The experimental research of Zhao et al. demonstrated that ACC inhibitors as a potential anticancer drug have been increasingly recognized over the past few years. ACC's variant inhibitor, 5-(14-alkaloxygen)-2-furanic acid (TOFA), is cytotoxic to cancer cells and dose dependent to induce apoptosis. To the best of our knowledge, other ACC inhibitors (e.g., PF-05175157, Soraphen A, and CP-640186) have not been examined in esophageal cancer models [68, 69]. In brief, the development of additional novel sensitive ACC inhibitors as antitumor drugs is required.

2.3.3. FASN. FASN is a crucial enzyme for the de novo synthesis of fatty acids, which plays an essential role in lipid metabolism and is correlated with tumor-related signaling pathways. In addition, it is capable of regulating the immune microenvironment, playing a certain role in epithelial-mesenchymal transition, and controlling tumor invasion and metastasis [38]. FASN expression in BE is significantly correlated with intestinal mucin phenotype, cell proliferation, accelerated angiogenesis, and cyclooxygenases-2 (COX-2) expression. FASN expression is likely to be a marker of an advanced risk of malevolence progression [39]. FASN upregulated in ESCC, and both knockdown and knockout of FASN significantly inhibited ESCC cell proliferation, which revealed a tumor exponent function for this gene in ESCC [40]. Downregulated FASN expression reduced the expansion and migration of esophageal cancer cells and should be considered a therapeutic strategy in esophageal cancer [41]. FASN may be an oncogenic protein in esophageal cancer. For instance, FASN is expressed at remarkably increased levels in esophageal cancer, and C93 can inhibit the growth of EC [81]. C75, a first-generation synthetic small-molecule inhibitor of FASN, inhibits OSCC proliferation [39].

2.3.4. SCDs. Steraryl coenzyme A desaturated enzyme (SCDs) refers to an endoplasmic reticulum (ER) protein catalyzing the conversion of saturated fatty acids (SFAs) into ∆9-monounsaturated fatty acids (MUFAs) [103]. SFAs and MUFAs have been found as the main components of mammalian cell lipids, which consist of phospholipids (PLs), diacylglycerol (DAG), triglycerides (TAGs), and cholesterol esters (CE) (e.g., the essential components of biomembrane, sources of energy, and signaling molecules). Densely proliferating cancer cells have a high demand for MUFAs, mainly for the synthesis of new membrane PL, TAG, and CE. In esophageal cancer, lipid levels of MUFAs (primarily phosphatidylcholine) increased, while SFAs and PUFAs decreased. The accumulation of MUFAs observed in cancerous tissue overlaps with higher levels of SCD1 [104, 105]. MUFAs are capable of directly regulating CSCs via the Wnt/β-catenin pathway, which is one of the critical signaling pathways in esophageal cancer stem cells [106–108]. SREBP1 also promotes proliferation and induces epithelial-interstitial transition by activating the SCD1-induced Wnt/β-catenin signaling pathway, which has a carcinogenic effect in ESCC [34]. So far, several targeted SCD1 inhibitors, including BZ36, A939572, CAY-10566, and MF-438, have acted on a wide variety of tumors in tumor therapy. It is found that Oxaliplatin combined with A939572 can promote SCD1 overexpression and regulate hippo/YAP signaling pathways, which may more significantly inhibit tumor growth and metastasis in patients with cancer [109]. Accordingly, CSC-targeting treatment combined with SCD1 inhibitors may also act as a novel approach to treat esophageal cancer CSCs.

2.3.5. SREBPs. The functions of SREBPs were confirmed as lipid synthetic transcription factors, specifically for synthesizing cholesterol and fatty acid [110]. SREBP1 turns out to be implicated in energy metabolism, including fatty acid metabolism, whereas SREBP2 is characterized by cholesterol synthesis. SREBP1 may equip the possibility for the diagnosis and therapy of ESCC. SREBP1 is required for generating ESCC cell expansion, migration, and aggression. Moreover, SREBP1 contributes to producing novel biomarkers and therapeutic targets for ESCC. SREBP1 exerts oncogenic effects in ESCC by stimulating proliferation and causing epithelial-mesenchymal transition through the SCD1-induced activation of the Wnt/β-catenin signaling pathway [34].

SREBP2, the head regulator for HMGCR, was upregulated in ESCC clinical samples. The overexpression of SREBP2 in ESCC cell lines boosted cancer cell growth, migration, and colony formation [42].

In esophageal squamous cancer, sterol regulatory element-binding transcription factor 1 (SREBF1), a critical regulatory protein for fatty acid metabolism, can regulate the synthesis of fatty acids, lipids, and glyphosate [111].

Moreover, SREBP1 contributes to producing novel biomarkers and therapeutic targets for ESCC. SREBP1 exerts oncogenic effects in ESCC by stimulating proliferation and causing epithelial-mesenchymal transition through the SCD1-induced activation of the Wnt/β-catenin signaling pathway [34].

SREBP2, the head regulator for HMGCR, was upregulated in ESCC clinical samples. The overexpression of SREBP2 in ESCC cell lines boosted cancer cell growth, migration, and colony formation [42].

In esophageal squamous cancer, sterol regulatory element-binding transcription factor 1 (SREBF1), a critical regulatory protein for fatty acid metabolism, can regulate the synthesis of fatty acids, lipids, and glyphosate [111].

The above findings further indicated the fine regulation of esophageal squamous cancer, providing other potential therapeutic targets for ESCC. For instance, fatostatin, an active metabolite of tamoxifen, significantly repressed tumorigenesis via downregulating SREBP1 and epithelial-to-mesenchymal transition (EMT) markers [82].

2.3.6. HMGCR

(1) Mevalonate Pathways and Processes. Cholesterol has been found as an essential element of lipid rafts, the primary venue for signaling regulation in cancer. Chelating membrane cholesterol is an efficacious anticancer strategy disrupting the functions of lipid rafts [43].

In the first step of identification, HMGCR, the speed-limiting enzyme of mevalonate pathway (MVP), is capable of converting HMG-CoA into mevalonate. In addition, MVP provides protein isoprenylation, which is critical to the downstream signal activity of small GTPases (Ras, Rho, or Rac) and to intracellular signal transduction [112]. Among MVP-targeted drugs, statins, as competitive inhibitors of HMGCR, regulate tumor cell growth and antitumor immune response. They can inhibit the proliferation of tumor cells and the migration and invasion of tumor cells.
Regardless of the timing of statin use and the pathological subtype of esophageal cancer, statin was found to be correlated with a significant reduction in mortality in patients with esophageal cancer [113]. In addition, statins could serve as an adjuvant anticancer agent to treat esophageal cancer [114]. In ESCC cells, HMG-CoA reductase is critical to tumor genetics of esophageal cancer since the knockdown of HMG-CoA reductase expression can inhibit the growth and migration of EC [35], thus supporting the application of statins as anticancer agents for esophageal cancer. With the use of statins, extracellular signal-regulated kinase activation could be reduced, cell nuclear antigen could be proliferated, and D1 expression could be circulated to induce the apoptosis of ESCC [115]. Furthermore, statins could minimize cell survival and proliferation, manifest crucial metastasis markers, and induce the apoptosis of ECA cells [116, 117]. Besides, statins could increase radiation sensitivity and reverse the epithelial-interstitial transition of esophageal cancer cells, which confirmed the potential effect of overcoming radiation impediment in EC [118, 119]. Complementary statin therapy has also been reported to lead to better quality-adjusted life expectancy of ECA patients at lower costs. For the above reasons, it can be a promising cost-effective treatment [120]. It has been consistently demonstrated that statin is capable of improving the prognosis of esophageal cancer patients. Thus, statins can serve as promising complementary anticancer agents for patients with EC.

2.3.7. CPT1. Carnitines play a significant function in carting long-chain fatty acids across the mitochondrial membranes and short-chain fatty acids across mitochondria into the cytosol and also take part in fatty acid oxidation (FAO) and energy metabolism [44]. The key rate-limiting enzyme of FAO, carnitine palmitoyltransferase I (CPT1), regulates FAO directly, thus stimulating cancer metabolic adaptation. Determining the changes in carnitine and CPT1 levels in patients with esophageal cancer may be considered as a novel screening method and a new treatment target for ESCC research results. Jin et al. discovered greatly enriched serum long-chain fatty acids in ESCC patients, thus confirming that the raised abundance of serum long-chain fatty acids might be the outcome of potent de novo fatty acid synthesis during expansion and metastasis of EC [45]. Shi et al. found a noticeable correlation between carnitine acyltransferase 1A (CPT1A) and poor prognosis in patients with ESCC, and CPT1A might be a predicting marker for ESCC [46]. Zhu et al. demonstrated that palmitoleic acid, palmitaldehyde, and isobutyl decanoate exhibited ideal diagnostic biomarkers [47]. Likewise, palmitoleic acid was indicated to exist in plasma metabolites of ESCC patients. In addition, α-methylacyl CoA racemase (AMACR) is also a long-chain fatty acid; its derivatives in FAO enzymes can be exploited to forecast neoplastic progression in BE [121].

2.4. Fatty Acids and Cholesterol Intake. Shyamsundar et al. reported that a chronic high-fat diet independently caused esophageal inflammation and metaplasia, the foremost steps in BE/EAC pathogenesis [119]. External fatty acids are carried into the esophageal cell via transportation means using specialized enzymes and proteins (CD36, low-density lipoprotein (LDL), and fatty acid-binding proteins 1 (FABP1)).

In general, cancer cells binding to membranes LDL-related receptors (LDLRs) via LDL are internalized and transported to advanced lysosomes. Ma et al. found that the LDL level is a negative predictive factor for ESCC. Further, LDL is an affordable and suitable biomarker that may help meet clinical requirements [70]. Then, lysosomal acid lipase (LAL) releases cholesterol to increase lipid metabolism. Low-density lipoprotein receptor-related protein 1B (LRP1B) will be removed in a wide range of tumors. New experimental results indicated that LRP1B most often occurs in esophageal cancer homologous deletion or hypermethylation transfer silencing via CpG island, thus resulting in the loss of function [122]. However, since LDL facilitates lymphatic metastasis, preoperative LDL serum levels are critical to predict ESCC results [70, 123]. In addition, low-density lipoprotein receptor-related protein 6 (LRP6) is considered a tumor promoter. The downregulation of LRP6 can inhibit cell migration, invasion, and EMT in ESCC cell lines [124].

CD36 refers to a cell marker initiating metastasis. Fatty acid receptor CD36 has been found as a marker and functional driver of lipid metabolic dependence metastasis [125]. ESCC cases show high levels of CD36 expression, which is significantly correlated with progression. If CD36 is artificially inhibited by intervention, the proliferation and invasiveness of ESCC cells will be significantly reduced. Since the viability of cells is dependent on the fatty acids produced under CD36 expression, ESCC cells with CD36 inhibition can only exploit specific essential amino acids (EAAAs) as a source of energy. Thus, CD36 can be a promising biomarker and therapeutic target in ESCC. Furthermore, FAs may be a crucial regulator of energy dependence in ESCC cells [31]. However, existing research data are insufficient to demonstrate the clinical availability of CD36 expression, so in-depth research should be conducted to clarify the clinical use of CD36 receptor in ESCC patients.

Fatty acid-binding proteins (FABPs) are present in a wide variety of tissues and play a vital role in fatty acid metabolism. FABP1 is a rich acid-binding protein and a marker of intestinal and liver cells. Existing studies have reported that peroxisome proliferator-activated receptors (PPARs) are capable of regulating FABP1 and are indispensable in cell division, signal transduction, proliferation, and differentiation. FABP1 has different expression levels in dysplasia and EAC. This marker can act as critical diagnostic aids to determine the condition of cancer progression [48].

2.5. Lipid Droplet Formation and Lipolysis. Excess lipid in cells does not exist in unsterilized free fatty acids (FFAs) since high levels of FFAs have cytotoxic potential. Accordingly, cells store excess fatty acids and cholesterol in the form of neutral and inert biomolecules (e.g., sterol esters and...
TGs in cellular structures), which are termed lipid droplets. As reported by recent studies, LD abundance is correlated with increased invasive tumors and chemotherapy resistance to tumors [101]. As indicated by experimental studies, in patients with esophageal cancer with no stress, the constant increase in lipolysis and triglyceride cycle arises from the changes in nutrients brought by cancer, instead of the tumor [126]. In addition, fatty tissue around the tumor can have an effect on tumor development. Obese people are at higher risk of certain cancers (esophageal cancer). Cancer-associated adipocytes (CAAs) secrete adiponectin that can facilitate the adhesion, migration, and invasion of tumor cells [127]. Cancer cells and CAAs also undergo a dynamic exchange of metabolites. In particular, lipolysis is an essential mechanism for tumor cells to promote the release of fatty acids through CAAs. Triglycerides (TGs) act via three lipase types, including adipose TG lipase (ATGL), hormone-sensitive lipase (HSL), and monoacylglycerol lipase (MAGL), thus leading to the release of FFAs and glycerin [128].

Monocacylglycerol O-acyltransferase 2 (MGAT2) refers to a component of monocacylglycerol acyltransferase (MGAT) or acyl-CoA that catalyzes the synthesis of diacylglycerol, which is a type of triacylglycerol. Diacylglycerol O-acyltransferase 2(DGAT2) interacts with LDs, which may catalyze localized TG synthesis for LD growth. MGAT2 is downregulated at irradiations in well or poorly differentiated ESCC cells [129].

As demonstrated by recent investigations, the interaction of DGAT2 and MGAT2 can lead to the biosynthesis of lipid substrates for TGs [130]. According to Carrossini et al., LD increased with EAC evolution, which arose from the exposure of the esophageal epithelium to the hazard factors correlated with BE and EAC [49].

Fatty acids released by CAA are transferred to cancer cells and exploited in energy production via β-oxidation. The high availability of adipocyte cells in the microenvironment supports tumor progression and uncontrolled growth [127]. In cancer cells, adipocyte cells act as significant sources of adiponectin and energy. Metabolic symbiosis mechanisms should be clarified, which can reveal novel therapeutic possibilities. LDs are the central organelle in excess lipid stores energy through esterification. Whether this mechanism plays a role in esophageal cancer should be verified by in-depth research.

2.6. Lipid Raft. The lipid rafts in the cell membrane create a platform for mediating lipid signals to facilitate the transfer. Cancer cells are capable of combining lipid metabolism to support host cells in a microenvironment and facilitate distant metastasis [102]. They are highly dynamic and can serve as selective signal transduction to mediate lipid metabolism, cell survival, adhesion, metastasis, and tumor progression. The relative abundance of saturated fatty acids primarily accounts for the liquid order of lipid rafts, thus inhibiting the synthesis of lipid raft-related lipids. Cholesterol is a vital segment of lipid rafts, the prior media for signaling regulation in cancer, and chelating membrane cholesterol has been proven as an effective anticancer approach disrupting the roles of lipid rafts [131]. Lipid rafts are enriched in sphingolipids, but subtle changes in the raft lipidome are likely to appear to recruit specific proteins that eventually trigger specific signaling events [132]. Cancer cells contain higher levels of intracellular cholesterol and lipid rafts than their normal nontumorigenic counterparts. Numerous signal transduction processes are involved in cancer development. For instance, Gong et al. discovered that NF-κB activation facilitated lipid raft construction in ESCC [133]. Lin et al. confirmed that repressing the construction of lipid raft-associated Ras-related C3 botulinum toxin substrate 1 (Rac1)/phosphatidylinositol 3-kinase (PI3K) p85α/ Akt signaling complexes could inhibit stromal cell-derivedfactor-1α (SDF-1α)-induced aggression of EC [134]. Song et al. reported flotillin-1 stimulates tumor necrosis factor-α receptor signaling and activation of NF-κB in ESCC [135].

2.7. Signaling Pathways Contributing to Lipid Metabolism Reprogramming. Pathways that maintain EC consist of Wnt/β-catenin, Notch, NF-κB, and Hippo. The above pathways are involved in maintaining tissue homeostasis, and the regular renewal of stem cells and the deregulation of the above pathways leads to the formation of EC. Aberrant signaling of the critical pathways was correlated with metabolic reprogramming of lipids in esophageal carcinoma. The specific process is shown in Figure 2).

2.7.1. NF-κB Signaling Pathway. The incidence of esophageal adenocarcinoma tends to increase during esophageal reflux inflammation, metaplasia, and dysplasia. Nuclear factor-kappa B (NF-κB) is critical to inflammation and tumorigenesis. As reported by existing studies, the NF-κB signaling pathway on the lipid raft of esophageal cancer cells plays a crucial role, and abnormal lipid metabolism changes can regulate the lipid raft’s function. The above studies revealed that NF-κB is of critical importance to lipid metabolism. On the one hand, N-3 polyunsaturated fatty acids can precisely change the composition of membrane lipid rafts. The enrichment of N-3 PUFA changes the transverse organization of membrane signaling components (lipid rafts), thereby affecting downstream signaling, T-cell activation, transcriptional activation, and cytokine secretion [136].

On the other hand, cholesterol acts as a crucial lipid component for the integrity and function of the raft, through which it locates receptors and promotes cell signaling [137]. Moreover, exogenous high-fat dietary intake also induces early BE in mice through lipid group remodeling [138]. The above theories all show that changes in cholesterol and fatty acids in cancer cells can affect a wide range of functions of lipid rafts. In addition, lipid rafts play an essential role in promoting the development of esophageal squamous cell carcinoma in NF-κB signaling. Fang et al. reported that the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) pathway is a vital pathway connecting
cancer growth through the NF-κB p65 subunit and COX-2 [139]. The STAT3 pathway could serve as a novel target for ESCC cancer treatment and prevention. As revealed by the latest experiments, aspirin (a nonsteroidal anti-inflammatory drug) blocked the increase in acid- and bile salt-induced NF-κB activation, p65 nuclear translocation of patients with esophageal squamous cells of BE [140].

2.7.2. PI3K/Akt/TOR Signaling Pathway. The PI3K/Akt signaling pathway facilitates cell growth through the activation of mTORC1. Positive expression of mTOR is significantly correlated with the depth of tumor infiltration, staging of TNM, degree of differentiation, and metastasis of lymph nodes in squamous cell carcinoma of the esophagus. Furthermore, the PI3K/Akt/TOR pathway is critical to lipid metabolism reprogramming in esophageal cancer. The PI3K/Akt/TOR pathway regulates the biosynthesis of fatty acids and cholesterol via SREBP1 and promotes key nascent lipids enzymes (e.g., ACC, FASN, and SCD) to varying degrees [103, 134]. Moreover, SREBP1 is correlated with increased tumorigenesis and poor prognosis of esophageal cancer cells [106]. According to Zhong et al., SREBP2 could promote ESCC cell growth, migration, and colony formation by regulating HMGCR and the synthesis of cholesterol. In addition, PI3K/Akt upregulates the expression of Forkhead Box O1 (FOXO1), thus leading to the beginning of SREBP transcription [135]. Turk et al., lysophosphatidylcholine acyltransferase 1 (LPCAT1) could regulate the expression of cholesterol synthase squalene monooxygenase (SQLE) by facilitating the activation of PI3K, promoting the entry of SREBP1 into the nucleus, and eventually achieving re-cholesterol metabolism reprogramming, thus promoting the occurrence and development of esophageal squamous cell carcinoma [136].

2.7.3. Wnt/β-Catenin Signaling Pathway. In the normal physiological state, the Wnt/β-catenin signaling pathway can regulate downstream genes involved in essential cell biological functions (e.g., cell proliferation, differentiation,
apoptosis, and cell death) [141]. However, numerous find-
ings suggested that abnormal β-catenin expression may be
poor underlying factors affecting esophageal cancer’s ability
to progress, metastasize, and invade [142].

Recent studies have reported the interactions between
the Wnt/β-catenin pathway and abnormal lipid metabolism
reprogramming, which include proliferation-activated re-
ceptor α (PPARα) that plays a certain role in fatty acid
transport and mitochondrial β-oxidation [139]. As reported
by Senni et al., β-catenin could determine the energy source
cells that are specifically used to support growth by inhib-
iting the regulation of PPARα [140]. According to the ex-
periment of Xu et al., PPARγ could regulate FAO by
negatively regulating CPT1A, that is, an essential enzyme for
FAO, thus having a further effect on the polarization of anti-
flammatory (M2) macrophages [141]. Moreover, abnor-
mal lipid metabolism reprogramming is capable of activ-
vating signaling pathways to promote the occurrence and
development of esophageal cancer. As indicated by Wang
et al., SREBP1/SCD1 could regulate proliferation, invasion,
and metastasis via the Wnt/β-catenin signaling pathway in
ESCC [27].

2.7.4. AMPK Signaling Pathway. AMPK refers to a central
regulator of cellular metabolism and energy homeostasis in
mammalian tissues [142]. When cellular energy levels de-
crease, AMPK is activated; then by activating critical en-
zymes involved in fatty acid metabolism (ACC1 and
SREBP1c), it further exerts its early anti-syntheticpro-
breakdown effect, thus leading to an increase in ATP
levels. In addition, hepatocyte nuclear factor 4 alpha
(HNF4α) is a crucial regulator of the oxidation of mito-
chondrial FAO, cholesterol, and lipoprotein metabolism
[143]. Barrett’s metaplasia is the only known morphological
precursor to esophageal adenocarcinoma, replacing the
stratified squamous epithelium with columnar epithelium.
Colley et al. found that AMPK could activate HNF4α,
thus facilitating a critical early step in Barrett’s metaplasia
[144]. According to the study by Mi et al., in the case of
intestinal mucin phenotype of BE, in which Barrett’s
glandular cells had a high COX-2 expression [99].

Yan et al., the effects arising from PUFAs on myeloid-
derived suppressor cells (MDSCs) were dependent on
STAT3 signaling, and blockage of STAT3 phosphorylation
nearly reversed the effect of PUFAs on MDSCs [143]. Li
et al. concluded that the effects arising from PUFAs on
MDSCs were dependent on STAT3 signaling, and that the
blocking of STAT3 phosphorylation nearly reversed the
effect of PUFAs on MDSCs. Moreover, COX-2, also cor-
related with JAK/STAT signaling, is involved in tumori-
genesis [144]. Fang et al. identified the JAK/STAT3 pathway
as an essential pathway linking cancer growth across the
NF-κB p65 and COX-2 subunits. The STAT3 pathway
could be a novel target for cancer treatment and prevention
in ESCC [139].

Zhao et al. reported that nimesulide downregulated
COX-2 and survived expression and improved caspase-3
expression in ESCC by activating JAK2/STAT3 channel
[147]. Ishimura et al. found that FASN was expressed in
the intestinal mucin phenotype of BE, in which Barrett’s
glandular cells had a high COX-2 expression [99].

2.7.5. JAK/STAT3 Signaling Pathway. As indicated by re-
cent reports, STAT3-mediated lipid metabolism takes on
a critical importance to cancer progression. According to

2.7.6. Hippo Signaling Pathway. The Hippo-YAP pathway
regulates mammals’ organ size, tissue homeostasis, as well as
tumorigenesis [145]. The transcriptional coactivators Yes-
associated protein 1/transcriptional coactivator with PDZ-
binding motif (YAP/TAZ) is a downstream transcriptional
coactivator of the Hippo signaling pathway. YAP/TAZ in-
teracts with mature SREBP1cs in the nucleus, thus enhancing
the transcriptional activity and upregulating the expressions
of crucial fatty acids and cholesterol enzymes (e.g., HMGCR
and FASN) [146]. When statin inhibits the activity of
HMGCR in the mevalonate pathway, the transcriptional
activity of YAP/TAZ is inhibited [148]. Moreover, SCD1
promotes the synthesis of unsaturated fatty acids, thereby
further activating the Wnt ligand and ultimately promoting
the accumulation of β-catenin and YAP/TAZ in the nucleus,
playing a role in transcriptional regulation [149]. In
esophageal cancer, the YAP1 protein is generally overex-
pressed and positively correlated with the histological
grading, staging, diameter, and overall and disease-free
survival of ESCC; the downregulation of YAP1 will pro-
mote the apoptosis of ESCC cells or inhibit their pro-
liferation and invasion [147].

2.8. The Link between Lipid Metabolism and Immune
Response in the Esophageal Cancer Microenvironment.

The esophageal mucosa, an organ directly exposed to the risk
of foodborne infection, has a unique group of innate im-
une cells that are critical to maintain esophageal stability
and carry out immune defense. ESCC is enriched in
immune-suppressive cell populations (e.g., Tregs; exhausted
CD8+ T cell, CD4+ T cell, and NK cells; M2 macrophages;
and DC cells) [150]. CD8+ T-cell infiltration has been
generally part of the host’s antitumor immune response,
whereas it can facilitate the exacerbation of chronic in-
flammation and the development of tumors. CD8+ T cells in
EAC patients may indicate poor inflammatory responses in
the surrounding tissue microenvironment, which can be
Conducive to the patients' prognoses [151]. CD8+ T cells lacking SREBP activity are expected to have insufficient cholesterol. Phospholipids and cholesterol, the raw materials in cell membranes, are insufficient to generate sufficient antigen stimulation, thus destroying the tumor-killing function of infiltrating CD8+ cytotoxic T cells. Regulatory T cells are capable of inhibiting antitumor immunity, limiting the protective immune monitoring of tumors, and facilitating the occurrence and development of tumors. Foxp3+ T cells can uptake more long-chain fatty acids (Tconv) than traditional T cells, which protect themselves from the potential damage of acylated FFA. Foxp3 and Toll-like receptor signaling can balance Treg cell anabolic metabolism for suppression [152].

As proven by the experiments by Liu et al., Treg cells improved the SREBP1-dependent metabolic fitness of tumor-promoting macrophages by repressing CD8+ T cell-derived interferon-γ [153]. M1 macrophages could induce FA synthesis, while anti-inflammatory signals favoring M2 macrophages would facilitate FAO [154, 155]. M2-like TAMs have been suggested to inhibit antitumor immunity, induce angiogenesis, and facilitate cell migration [156]. An increased proportion of TAMs in ESCA in esophageal cancer is correlated with high aggressiveness and poor prognosis of patients [157].

As revealed by Zhou et al., monocyte chemotactic protein 2 (MCP2) secreted by M2 macrophages could activate the NF-κB signaling pathway, facilitate ESCC cell migration and invasion, and induce the EMT process [158]. The specific process is shown in Figure 3.

2.9. Esophageal Cancer Lipid Metabolism on T Cells in the Immune Microenvironment. Different subsets of T cells consist of effector cells (Teff), regulatory cells (Treg), and memory cells (Tmen). Different metabolic characteristics have an effect on the differentiation and function of T cells. Existing studies have shown that Teff cells rely on FAS. In contrast, Foxp3+ Treg cells and CD8+ Tmen cells depend on the production of long-chain fatty acids (LCFAs). In EC, the B7/CTLA-4 signaling pathway activates the tumor or matrix derived from chemokines (e.g., CCL20 (C-C motif chemokine ligand 20)) [159], activating and recruiting Treg. Subsequently, Treg is capable of secreting immunosuppressive factors interleukin-10 (IL-10), transforming growth factor beta (TGF-β) [160], etc. Moreover, lipid accumulation in immune cells can facilitate oxidative metabolism. For instance, lipid accumulation in dendritic cells reduces their ability to process and present antigens, thus reducing the ability to stimulate T cells, which reveals that lipid accumulation in the tumor microenvironments can have an effect on the function of immune cells. In addition, high esterification rates of cholesterol in tumors can reduce the response of T cells. Elevated cholesterol levels of CD8+ T-cell membranes are likely to facilitate their proliferation and improve their effect function, which is consistent with the role played by FAO as indicated by our consideration. As reported by the experiments by Pearce et al., mice lacking TNF receptor- associated factor 6 (TRAF6) could not raise FAO, and the production of Tmen also had severe defects. AMPK could reverse the above situation, since it promoted the induction of FAO in CD8+ T cells, while playing the most critical role in facilitating the production of Tmen. AMPK is capable of regulating two pathways (i.e., FAS and FA). To be specific, it is capable of inhibiting FAS by reducing the formation of malonyl-CoA of ACC1, while it can hinder ACC2 (correlated with mitochondria), a rate-limiting enzyme in FAO. It has been confirmed that there is a direct correlation between AMPK activation and the upgrading of FAO via the classic ACC2-CPT1 axis in liver cells. Whether there is a related lipid metabolism pathway in esophageal cancer should be explored in depth. Besides, AMPK can indirectly promote FAO by upregulating the expression of CPT1 in a peroxisome proliferator-activated receptors (PPAR)-peroxisome proliferator-activated coactivator (PGC)-1-dependent mechanism. A wide range of fatty acids have been reported to facilitate the differentiation and proliferation of T cells in the intestine. Medium and long-chain fatty acids are capable of supporting the differentiation of pro-inflammatory Th1 and Th17 cells, while short-chain fatty acids facilitate the development of Treg cells. The divergence of metabolic reprogramming is of high importance to effectively label the fate of different T cells. Furthermore, strengthening FAO by improving AMPK activity or inhibiting rapamycin's mammalian targets will increase the number of memory T cells. Whether the functional results of the programmed cell death protein-1 (PD-1) connection are correlated with T-cell reprogramming to specific metabolic pathways remains unclear. In our previous study, we have investigated the metabolism of T cells receiving PD-1 signals and found that they did not play a certain role in the metabolism of glycolytic enzymes, glutamine hydrolysis, or branched-chain amino acids, but showed higher FAO rates. Moreover, FAO maintains the survival and persistence of PD-1 signaling T cells in patients with chronic infection and cancer and reverses PD-1 blocking and revitalizes their abilities [161].

Our results revealed the accumulation of cholesterol, phospholipids, and saturated phospholipids in the T-cell receptor activation domain, which confirmed that lipid components in the immune cell membrane are involved in their function and signal transduction. CD8+ T cells could facilitate inflammation and tumor development in esophageal cancer and reduce tumor growth via cancer monitoring. The exact mechanism of cytotoxic CD8+ T cells impacted by gastro-esophageal reflux disease may be complex. According to existing EAC studies, the abundance of CD8+ tumor-infiltrating lymphocytes (TILs) is correlated with prolonged survival, better pathological responses to neoadjuvant chemotherapy, lower lymph node metastasis rates, and better prognosis. In general, cytotoxic CD8+ T cells could release interferon, granzyme A, granzyme B, and Fas ligand to induce the apoptosis of the target cells [162]. Collectively, directly targeting cellular FA metabolism may serve as a promising strategy to control T-cell response in vivo. However, in subsequent studies, the role of FAS and FAO in T-cell subsets and other immune cell types should be further analyzed, and...
the effects arising from FA metabolism in different stages of inflammatory response should be clarified.

2.10. Esophageal Cancer Lipid Metabolism on Tumor-Associated Macrophages (TAMs) in the Immune Microenvironment. Macrophages are an important part of the tumor immune system. Tumor-associated macrophages can be enlisted and cultivated to exert antitumor or proto-tumor functions during tumor initiation and progression [163]. Esophageal cancer is not an exception to this rule. Inflammatory (M1) macrophages are capable of sustaining inflammatory responses and killing pathogens, relying primarily on aerobic glycolysis and fatty acid biosynthesis. Using predominantly aerobic glycolysis and fatty acid production, inflammatory (M1) macrophages may maintain inflammatory responses and destroy pathogens. Experimental studies by Jiang et al. found that M1 macrophages can be utilized to predict a patient’s prognosis for ESCC by preventing ESCC cell migration and invasion [164]. By integrating transcriptomic and lipid metabolomic profiling, a large number of fatty acids and lipid mediators are pan-agonists of peroxisome proliferator-activated receptors (PPARs), and arachidonic acid, unsaturated fatty acid, significantly affects esophageal squamous cell carcinoma by regulating peroxisome proliferator-activated receptor gamma (PPARγ) and OXPHOS M2 polarization in macrophages [165].

Anti-inflammatory (M2) macrophages, in contrast, mediate tissue repair and inflammation lysis by switching their metabolism to FAO and oxidative phosphorylation [166]. Yuan et al. found that M2-liketumor-associated macrophages could generate an immunosuppressive tumor microenvironment by secreting fibrinogen-like protein 2 (FGL2) to induce the occurrence and progression of esophageal cancer [157]. In addition, M2 macrophages might encourage ESCC cell invasion and migration, leading to epithelial-mesenchymal transition (EMT) and a poor prognosis for ESCC patients [167, 168]. Thus, the specific mechanism by which lipid metabolism enables TAMs to actively or passively change their phenotype to adapt to the microenvironment is poorly understood, but this property could provide not only survival opportunities for tumor cells but also facilitate tumor therapy.

2.11. Esophageal Cancer Lipid Metabolism on Dendritic Cells (DC) in the Immune Microenvironment. The DCs distributed in the esophageal mucosa are generally

Figure 3: Lipid metabolism reprogramming in the esophageal cancer microenvironment affects the anti-/pro-tumoral functions of immune cells. MDSC, marrow-derived suppressor cells; DCs, dendritic cells; FAO, fatty acid oxidation; FAS, fatty acid synthesis; TAMs, tumor-associated macrophages; FFA, free fatty acid; Tregs, regulatory T cells; NK Natural killer cells; AMPK, AMP-activated protein kinase; IL-10, interleukin 10; TGF-β, transforming growth factor-β; STAT3, transcription 3; LPL, lipoprotein lipase; NF-κB, nuclear factor; FABPs, fatty acid-binding proteins; LRP4, lipoprotein receptor-related protein 4; PPAR, peroxisome proliferator-activated receptors.
Langerhans cells (LCs), which mature rapidly into specialized atarial premature complexes (APCs) after capturing tumor-associated antigens, thus leading to T-cell activation and immune response [169]. DC immune function in EC patients is impaired both at the circulation and tumor sites, accompanied by decreased CD80 and CD86 expression [170]. The above infiltrations of a decrease in DC activity and function are correlated with the overexpression of the mutated p53 protein in tumors [171]. The study by Brix S et al. demonstrated that differences in dietary fatty acids affect the overall level of CD4(+) T-cell activation induced by dendritic cells. Moreover, DC stimulation can also trigger changes in CD80 and CD86 levels [172]. There was a significant increase in DC density in adenocarcinoma compared to benign BE, thus revealing the potential of DC in EAC dysplasia and tumorigenesis [173].

Among the tolerated DCs, an increase in OXPHOS and FAO is correlated with IL-6. The experiments of Zhao et al. demonstrated that fibroblasts promote the production of monocytic-myeloid-derived suppressor cells (M-MDSCs) by activating the STAT3 signal secretion of IL-6 and emphasized that fibroblasts work together with M-MDSCs to promote the production of cisplatin resistance, thus providing a potential opportunity for inhibiting STAT3 signal reversal resistance in ESCC [174]. Tumor-derived FAs are capable of increasing OXPHOS and FAO through CPT1A transport or activation of PPARα. The activation of PPARα can also facilitate the formation of LD, which has a higher oxidation content of PUFA. According to the experiments of Wang et al., the expression levels of PPAR-α in BE and esophageal adenocarcinoma samples were 5.9130 and 2.0314 times higher than those of normal esophageal squamous epithelial cells, respectively. The upregulated expression of PPAR-γ may be critical to develop BE and ECA from normal cells [175].

Exogenous FAs are transported through macrophage receptor 1 (MSR1) and fatty acid-binding protein-4 (FABP4), supplementing the above LFs and increasing their oxidized PUFA content. The above LDs and tumor-derived FAs themselves impair cross-presentation by inhibiting MHCII surface expression. Inflammatory responses occur at the early stages of EAC and even in BE. DCs significantly impact the immune response of esophageal adenocarcinoma [176]. Changes in fatty acid metabolism affect the “switch” function of DC, whether immune activation or immunosuppression is selected. Moreover, wingless-type protein 5a (Wnt5a) can add FAO and OXPHOS by downregulating PPARy [177]. As indicated by the experimental studies of Lyros et al., abnormal regulation of the Wnt5a receptor tyrosine kinase-like orphan receptor 2 (ROR2) signaling pathway could facilitate the development of Barrett-associated esophageal adenocarcinoma [178]. As reported by Wu et al., Wnt5a can improve the invasive ability of ESCC cells via a wide variety of signaling pathways [179].

2.12. Esophageal Cancer Lipid Metabolism on Myeloid-Derived Suppressor Cells (MDSCs) in the Immune Microenvironment. Tumor cells can facilitate fatty acid uptake and synthesis in the TME, recruiting fat cells to produce excess exogenous fatty acids, thus creating a lipid-rich environment for the infiltration of MDSCs. MDSCs then adopt FAO as their primary energy. Lipid-rich TME can expedite the development of MDSCs and enhance their immunosuppressive function. As reported by existing studies, tumor-derived cytokines (granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF)) subsequently can induce the expression of lipid transporters via the STAT3 and STAT5 signaling pathways, thus increasing the uptake of high concentrations of lipids in the tumor microenvironment. Intracellular lipid accumulation increases oxidative metabolism and activates immunosuppressive mechanisms. Tumor-associated MDSCs upregulate FAO as the primary energy source. Moreover, CD36 uptakes fatty acids and supports the expression of FAO key enzymes (CPT-1). Lipid metabolism is correlated with the inhibitory function of MDSCs. Fatty acid uptake, fatty acid β-oxidation (FAO), fatty acid synthesis, and lipogenesis increased MDSCs, leading to an upregulation of immunosuppressive function [180]. Inhibition of the STAT3 or STAT5 signaling pathway or deletion of the fatty acid transport CD36 gene inhibits the activation of oxidative metabolism and induction of immunosuppressive function in tumor infiltration MDSCs and leads to delays in tumor growth dependent on CD8+ T cells [181]. Liu et al. experimentally demonstrated that upregulation of phosphorylated STAT3 (p-STAT) and phosphorylated STAT5 (p-STAT) expression might be correlated with esophageal squamous cell carcinoma development [182]. In patients with ESCC, the number of circulating MDSCs is elevated, accompanied by high expression of programmed death-ligand 1 (PD-L1). MDSCs exert immunosuppressive effects on T cells through the PD-1/PD-L1 pathway and are correlated with tumor burden, lymph node metastasis, and tumor staging [183]. Adeshakin et al. demonstrated that fatty acid transporter 2 (FATP2) could endow PMN-MDSCs with the function in cancer by upregulating arachidonic acid metabolism. FATP2 plays a crucial role in regulating lipid accumulation-induced oxygen species in MDSCs, and targeting FATP2 in MDSCs can serve as a novel therapeutic method to enhance anti-PD-L1 cancer immunotherapy [184].

2.13. Esophageal Cancer Lipid Metabolism on NK Cell in the Immune Microenvironment. NK cells refer to the first responders to innate immune responses. Pro-inflammatory cytokines secreted in the tumor immune microenvironment can activate NK cells and recruit more immune cells [185]. Studies have shown that NK cell infiltration density in EC TME positively correlated with overall survival (OS) and good postoperative prognosis [186, 187]. NK cells in EC TME are capable of recognizing and killing tumor cells via the NKP30/B7-H6 pathway, thus primarily facilitating NK cell-mediated immune responses [186]. However, lipid metabolism is critical to the immune microenvironment of esophageal cancer. As indicated by Lim Kee et al., the deoxycholic acid (DCA) also stimulated the production of
interleukin-6 (IL-6) and interleukin-8 (IL-8) in esophageal adenocarcinoma cells via raft-related signaling, thus facilitating esophageal metaplasia and dysplasia [188]. As proven by the experiments by Wu et al., the activation of STAT3 signaling by IL-6 and IL-8 secretion led to the down-regulation of receptors (NK protein 30 (NKP30) and NK group 2D (NKG2D) receptors) on the surface of activated NK cells, thus leading to impaired NK cell function and ultimately resulting in the development of esophageal squamous cell carcinoma [189].

After NK cells were activated, the mTORC1 signaling pathway was modulated to produce interferon-gamma (IFNγ) and granzyme B, which performed their effect function [190]. Their activation was consistent with increased ATP citrate lyase (ACL) expression and citric acid transport to cytoplasm, correlated with acetylation and epigenetic control [191]. According to the experimental studies of Carrossini et al., in BE and EAC, associated inflammatory stimulation would lead to a gradual increase in LD and a significant increase in IL-8 secretion. This phenomenon reveals an interaction between lipid droplets and inflammatory mediators, thus facilitating BE and EAC's occurrence and development [49]. Moreover, exogenous lipids could disrupt this metabolic program and have a negative effect on their effector function and ability to respond to stimuli, especially in the case of obesity [192–194].

2.14. Esophageal Cancer Lipid Metabolism on Cancer-Associated Fibroblasts (CAFs) in the Immune Microenvironment. CAFs have been more commonly induced in EMT [195]. CAFs secrete immunosuppressive and pro-angiogenesis factors in TME [68, 69], which has been found in recent literature and thus indicated that they may play a role in lipid breakdown and chemotherapy resistance in esophageal cancer. As demonstrated by the experiments of Qiao et al., IL-6, primarily from cancer-associated fibroblasts, upregulated chemokine receptor type 7 (CXCR7) expression through activators of the STAT3/NF-KB pathway, which could play a critical role in chemical resistance [196]. As reported by a previous study, fat cells, once activated by cancer cells, will eventually secrete higher levels of pro-inflammatory cytokines (e.g., IL-6) [197, 198]. Cancer cells could also secrete the above pro-inflammatory cytokines and help induce the release of fatty acids stored in fat cell triglycerides since they are considered strong lipolytic factors [199, 200]. The upregulation of IL-6 can amplify the metabolic cross-disorder STAT3 pathway between the two cells through the IL-6 signal, and CD36 has recently been shown to be a downstream target for activating STAT3, which will further promote fatty acid uptake of cancer cells [201, 202]. If so, metabolically activated adipose tissue macrophages also secreting IL-6 at high levels may play a role in this axis [203]. As demonstrated by Zhao et al., cancer-associated fibroblasts induce bone marrow-derived macrophages via the IL-6/STAT3 pathway to facilitate drug resistance in cisplatin of esophageal squamous cell carcinoma [174]. Zhang et al. confirmed the chemical tolerance of cancer-associated fibroblasts through FOXO1/transforming growth factor (TGF-β1) signaling ring-mediated esophageal squamous cell carcinoma [204]. A FOXO1 transcription factor is found to play a vital part in cellular stress response and is correlated with plentiful nutrient regulation processes. FOXO1 regulates lipid metabolism in adipose tissue by regulating fat cell size and the expression of AT-specific genes, including ATGL, which is a rate-limiting enzyme playing a role in the breakdown and storage of TG stored into LDs [205]. FOXO1 is critical to fatty acid-induced oxidative stress in fat cells [206].

3. Conclusion

In this review, we elucidate how abnormal lipid metabolism has an effect on the occurrence and development of esophageal cancer. This review is original and innovative and will present more insights into the pathogenesis of esophageal cancer. Hopefully, this review can lay a theoretical basis for improving ESCC prognosis models, clarifying drug resistance mechanisms, and formulating corresponding targeted therapies.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ESCC | Esophageal squamous cell carcinoma |
| EAC | Esophageal adenocarcinoma |
| TME | Tumor microenvironment |
| EC | Esophageal cancer |
| BE | Barrett’s esophagus |
| GERD | Complication of gastroesophageal reflux disease |
| PUFAs | Polyunsaturated fatty acids |
| NRF2 | Nuclear factor erythroid 2 like 2 |
| ACSS2 | Acetyl-CoA synthetase short-chain family members 2 |
| FAs | Fatty acids |
| PI3K/AKT | Phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT)-mechanistic target of rapamycin (mTOR) signaling |
| ACBP | Acetyl-CoA-binding protein |
| 1-ACBP | 1-Acetyl-CoA-binding protein |
| B-ACBP | B-Acetyl-CoA-binding protein |
| PBR | Peripheral β-CoA-binding protein |
| SREBPs | Sterol regulatory element-binding protein |
| FBP1 | Fructose-1,6-biophosphatase |
| FASN | Fatty acid synthase |
| ACC1 | Acetyl-CoA carboxylase 1 |
| SREBP1C | Sterol regulatory element-binding protein 1C |
| SCD1 | Stearoyl-CoA desaturase 1 |
| SREBP2 | Sterol regulatory element-binding protein 2 |
| HMGCR | Hydroxy-3-methylglutaryl-CoA reductase |
| AMPK | AMP-activated protein kinase |
| PCNA | Proliferating cell nuclear antigen |
| NS | Nutritional stress |
| ACC2 | Acetyl-CoA carboxylase 2 |
Disclosure

Meng-Ying Cui is the first author, and Xing Yi is the first co-author.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Meng-Ying Cui conceived and designed the research. Meng-Ying Cui downloaded and analyzed the data and wrote the draft. Meng-Ying Cui and Xing Yi participated in the data analysis. All authors revised the manuscript and read and approved the manuscript for publication. Meng-Ying Cui and Xing Yi contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant no. 81770212, by Dr. Dan-Xia Zhu) and Changzhou City Health Commission Major Scientific and Technological Projects (Grant no. ZD201901, by Jun Wu).
References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[2] M. M. Cao and W. Q. Chen, “Prevalence and prevention and control of malignant tumors in China,” Chinese Journal of Clinical Oncology, vol. 46, no. 3, pp. 145–149, 2019.

[3] C. C. Abnet, M. Arnold, and W. Q. Wei, “Epidemiology of esophageal squamous cell carcinoma,” Gastroenterology, vol. 154, no. 2, pp. 360–373, 2018.

[4] R. S. Chen, K. X. Sun, S. W. Zhang et al., “Epidemiological situation of malignant tumors in China in 2015,” Chinese Journal of Oncology, vol. 1, no. 2019, pp. 19–28, 2019.

[5] H. Zeng, W. Chen, R. Zheng et al., “Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries,” Lancet Global Health, vol. 6, no. 5, pp. e555–e567, 2018.

[6] D. J. Uhlenhopp, E. O. Then, T. Sunkara, and V. Gaduputi, “Epidemiology of esophageal cancer: update in global trends, etiology and risk factors,” Clinical Journal of Gastroenterology, vol. 13, no. 6, pp. 1010–1021, 2020.

[7] H. L. Wang, P. F. Liu, J. Yue et al., “Somatic gene mutation signatures predict cancer type and prognosis in multiple cancers with pan-cancer 1000 gene panel,” Cancer Letters, vol. 470, pp. 181–190, 2020.

[8] Z. J. Zhu, Z. Qi, J. Zhang et al., “Untargeted metabolomic analysis of esophageal squamous cell carcinoma discovers dysregulated metabolic pathways and potential diagnostic biomarkers,” Journal of Cancer, vol. 11, no. 13, pp. 3944–3954, 2020.

[9] K. Garber, “Energy deregulation: licensing tumors to grow,” Science, vol. 312, no. 5777, pp. 1158–1159, 2006.

[10] J. Storch and B. Corsico, “The emerging functions and mechanisms of mammalian fatty acid-binding proteins,” Annual Review of Nutrition, vol. 28, no. 1, pp. 73–95, 2008.

[11] J. A. Menendez and R. Lupu, “Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis,” Nature Reviews Cancer, vol. 7, no. 10, pp. 763–777, 2007.

[12] Q. He, H. Sun, F. Li, and N. Liang, “Obesity and risk of differentiated thyroid cancer: a large-scale case-control study,” Clinical Endocrinology, vol. 91, no. 6, pp. 869–878, 2019.

[13] T. J. Grevengoed, E. L. Klett, and R. A. Coleman, “Acyll-coa metabolism and partitioning,” Annual Review of Nutrition, vol. 34, pp. 1–30, 2014.

[14] H. Zhang, L. Wang, Z. Hou et al., “Metabolomic profiling reveals potential biomarkers in esophageal cancer progression using liquid chromatography-mass spectrometry platform,” Biochemical and Biophysical Research Communications, vol. 491, no. 1, pp. 119–125, 2017.

[15] Japan Esophageal Society, “Japanese classification of esophageal cancer, 11th edition: part I,” Esophagus, vol. 14, no. 1, pp. 37–65, 2017.

[16] R. C. Fitzgerald, M. di Pietro, K. Ragnath et al., “British society of gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus,” Gut, vol. 63, no. 1, pp. 7–42, 2014.

[17] T. Kazui, H. Wada, and H. Fujita, “Thoracic and cardiovascular surgery in Japan during 2003: annual report by the Japanese association for thoracic surgery,” The Japanese Journal of Thoracic and Cardiovascular Surgery, vol. 53, no. 9, pp. 517–536, 2005.

[18] K. Liu, M. Jiang, Y. Lu et al., “Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells,” Cell Stem Cell, vol. 12, no. 3, pp. 304–315, 2013.

[19] M. Jiang, H. Li, Y. Zhang et al., “Transitional basal cells at the squamous-columnar junction generate Barrett’s oesophagus,” Nature, vol. 550, no. 7677, pp. 529–533, 2017.

[20] M. Quante, G. Bhagat, J. A. Abrams et al., “Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia,” Cancer Cell, vol. 21, no. 1, pp. 36–51, 2012.

[21] Z. Gu, K. Shan, H. Chen, and Y. Q. Chen, “N-3 polyunsaturated fatty acids and their role in cancer chemoprevention,” Current Pharmacology Reports, vol. 1, no. 5, pp. 283–294, 2015.

[22] M. Azrad, C. Turgeon, and W. Demark-Wahnefried, “Current evidence linking polyunsaturated fatty acids with cancer risk and progression,” Frontiers in Oncology, vol. 3, p. 224, 2013.

[23] J. O. Odera, Z. Xiong, C. Huang et al., “Nrf2/Accs2 axis mediates the metabolic effect of alcohol drinking on esophageal squamous cell carcinoma,” Biochemical Journal, vol. 477, no. 16, pp. 3075–3089, 2020.

[24] J. A. Nettleton, I. A. Brouwer, R. P. Mensink, C. Diekman, and G. Hornstra, “Fats in foods: current evidence for dietary advice,” Annals of Nutrition and Metabolism, vol. 72, no. 3, pp. 248–254, 2018.

[25] M. Chen and J. Huang, “The expanded role of fatty acid metabolism in cancer: new aspects and targets,” Precision Clinical Medicine, vol. 2, no. 3, pp. 183–191, 2019.

[26] P. Somasundar, D. Riggs, B. Jackson, L. Vona-Davis, and D. W. McFadden, “Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms,” The American Journal of Surgery, vol. 186, no. 5, pp. 575–578, 2003.

[27] S. Ma, B. Zhou, Q. Yang et al., “A transcriptional regulatory loop of master regulator transcription factors, PPARG, and fatty acid synthesis promotes esophageal adenocarcinoma,” Cancer Research, vol. 81, no. 5, pp. 1216–1229, 2021.

[28] A. De Ceglie, D. A. Fisher, R. Filiberti, S. Blanchi, and M. Conio, “Barrett’s esophagus, esophageal and esophago-gastric junction adenocarcinomas: the role of diet,” Clinics and Research in Hepatology and Gastroenterology, vol. 35, no. 1, pp. 7–16, 2011.

[29] D. He, X. Huang, Z. P. Wang, D. Chen, J. Chen, and C. Y. Duan, “Dietary fat intake and risk of esophageal adenocarcinoma, gastric cardia adenocarcinomas: the role of diet,” Annals of Surgical Oncology, vol. 28, no. 2, pp. pp. 1217–1227, 2021.
[33] Y. He, R. Hua, B. Li, H. Gu, Y. Sun, and Z. Li, "Loss of Fbp1 promotes proliferation, migration, and invasion by regulating fatty acid metabolism in esophageal squamous cell carcinoma," Aging (Albany NY), vol. 13, no. 4, pp. 4986–4998, 2020.

[34] J. Wang, R. Ling, Y. Zhou et al., "Srebp1 silencing inhibits the proliferation and motility of human esophageal squamous carcinoma cells via the Wnt/B-catenin signaling pathway," Oncology Letters, vol. 20, no. 3, pp. 2855–2869, 2020.

[35] C. Zhong, L. Fan, F. Yao, J. Shi, W. Fang, and H. Zhao, "Hmgcr is necessary for the tumorigenicity of esophageal squamous cell carcinoma and is regulated by myc," Tumor Biology, vol. 35, no. 5, pp. 4123–4129, 2014.

[36] J. R. Moffett, N. Puthillathu, R. Vengilote, D. M. Jaworski, and A. M. Namboodiri, "Acetate revisited: a key biomolecule at the nexus of metabolism, epigenetics, and oncogenesis—part 2: acetate and Accs2 in health and disease," Frontiers in Physiology, vol. 11, Article ID 580171, 2020.

[37] M. Lei, Y. Zhou, D. Wu et al., "ACSS2/AMPK/PCNA pathway-driven proliferation and chemoresistance of esophageal squamous carcinoma cells under nutrient stress," Molecular Medicine Reports, vol. 20, no. 6, pp. 5286–5296, 2019.

[38] J. Zhang, Y. Song, Q. Shi, and L. Fu, "Research progress on FASN and MGIL in the regulation of abnormal lipid metabolism and the relationship between tumor invasion and metastasis," Frontiers of Medicine, vol. 15, no. 5, pp. 649–656, 2021.

[39] N. Ishimura, Y. Amano, A. A. Sanchez-Siles et al., "Fatty acid synthase expression in Barrett’s esophagus: implications for carcinogenesis," Journal of Clinical Gastroenterology, vol. 45, no. 8, pp. 665–672, 2011.

[40] X. Wang, J. Tian, Q. Zhao et al., "Functional characterization of a low-frequency V1937i variant in FASN associated with susceptibility to esophageal squamous cell carcinoma," Archives of Toxicology, vol. 94, no. 6, pp. 2039–2046, 2020.

[41] Y. Zhou, C. Niu, Y. Li et al., "Fatty acid synthase expression and esophageal cancer," Molecular Biology Reports, vol. 39, no. 10, pp. 9733–9739, 2012.

[42] C. Zhong, L. Fan, Z. Li, F. Yao, and H. Zhao, "SREBP2 is upregulated in esophageal squamous cell carcinoma and co-operates with c-Myc to regulate HMGCR expression," Molecular Medicine Reports, vol. 20, no. 4, pp. 3003–3010, 2019.

[43] X. Zhu, K. Wang, G. Liu et al., "Metabolic perturbation and potential markers in patients with esophageal cancer," Gastroenterology Research and Practice, vol. 2017, Article ID 5469597, 9 pages, 2017.

[44] P. R. Borum, "Changing perspective of carnitine function and the need for exogenous carnitine of patients treated with hemodialysis," The American Journal of Clinical Nutrition, vol. 64, no. 6, pp. 976–977, 1996.

[45] H. Jin, F. Qiao, L. Chen, C. Lu, L. Xu, and X. Gao, "Serum metabolomic signatures of lymph node metastasis of esophageal squamous cell carcinoma," Journal of Proteome Research, vol. 13, no. 9, pp. 4091–4103, 2014.

[46] Z. Z. Shi, J. W. Liang, T. Zhan et al., "Genomic alterations with impact on survival in esophageal squamous cell carcinoma identified by array comparative genomic hybridization," Genes, Chromosomes and Cancer, vol. 50, no. 7, pp. 518–526, 2011.

[47] Q. Zhu, L. Huang, Q. Yang et al., "Metabolomic analysis of exosomal-markers in esophageal squamous cell carcinoma," Nanoscale, vol. 13, no. 39, pp. 16457–16464, 2021.

[48] S. Srivastava, F. Kern, N. Sharma et al., "FABP1 and HEPAR expression levels in Barrett’s esophagus and associated neoplasia in an Asian population," Digestive and Liver Disease, vol. 49, no. 10, pp. 1104–1109, 2017.

[49] N. Carrossini, N. M. De Costa, E. Andrade-Barreto et al., "Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors," Scientific Reports, vol. 11, no. 1, p. 981, 2021.

[50] S. Y. Zhao, X. M. Zhang, and H. S. Ma, "Expression and its clinical significance of AMP-activated protein kinase in esophageal squamous cell carcinoma," Journal of Sichuan University. Medical Science Edition, vol. 44, pp. 550–553, 2013.

[51] Z. Tracz-Gaszewska and P. Dobrzyn, "Stearoyl-CoA desaturase 1 as a therapeutic target for the treatment of cancer," Cancers, vol. 11, p. 948, 2019.

[52] M. Zemanova, M. Vecka, L. Petruželka, B. Staňková, A. Žák, and M. Zeman, "Plasma phosphatidylcholines fatty acids in men with squamous cell esophageal cancer: chemoradiotherapy improves abnormal profile," Medical Science Monitor, vol. 22, pp. 4092–4099, 2016.

[53] Y. Zhao, L. Xu, X. Wang, S. Niu, H. Chen, and C. Li, "A novel prognostic mRNA/MiRNA signature for esophageal cancer and its immune landscape in cancer progression," Molecular Oncology, vol. 15, no. 4, pp. 1088–1109, 2021.

[54] J. Wang and Y. Li, "CD36 tango in cancer: signaling pathways and functions," Theranostics, vol. 9, no. 17, pp. 4893–4908, 2019.

[55] F. Shao, X. Bian, H. Jiang et al., "Association of phosphoenolpyruvate carboxykinase 1 protein kinase activity-dependent sterol regulatory element-binding protein 1 activation with prognosis of oesophageal carcinoma," European Journal of Cancer, vol. 142, pp. 123–131, 2021.

[56] J. Bremer, "Carnitine-metabolism and functions," Physiological Reviews, vol. 63, no. 4, pp. 1420–1480, 1983.

[57] X. Li, L. Zhao, M. Wei et al., "Serum metabolomics analysis for the progression of esophageal squamous cell carcinoma," Journal of Cancer, vol. 12, no. 11, pp. 3190–3197, 2021.

[58] J. Xu, J. Li, R. Zhang et al., "Development of a metabolic pathway-based pseudo-targeted metabolomics method using liquid chromatography coupled with mass spectrometry," Talanta, vol. 192, pp. 160–168, 2019.

[59] J. Xu, Y. Chen, R. Zhang et al., "Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers," Molecular & Cellular Proteomics, vol. 12, no. 5, pp. 1306–1318, 2013.

[60] M. Tao, J. Luo, T. Gu et al., "LPCTAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma," Cell Death & Disease, vol. 12, no. 9, p. 845, 2021.

[61] H. Guo, B. Wang, K. Xu et al., "m6A reader HNRNPA2B1 promotes esophageal cancer progression via up-regulation of ACYL and ACC1," Frontiers in Oncology, vol. 10, Article ID 553045, 2020.

[62] S. Zhang, X. Lu, C. Hu et al., "Serum metabolomics for biomarker screening of esophageal squamous cell carcinoma and esophageal squamous dysplasia using gas chromatography-mass spectrometry," ACS Omega, vol. 5, pp. 26402–26412, 2020.

[63] W. Ma, S. Wang, T. Zhang et al., "Activation of choline kinase drives aberrant choline metabolism in esophageal..."
squamous cell carcinomas,” Journal of Pharmaceutical and Biomedical Analysis, vol. 155, pp. 148–156, 2018.

[64] K. T. Kuo, H. W. Wang, T. Y. Chou et al., “Prognostic role of PGE2 receptor EP2 in esophageal squamous cell carcinoma,” Annals of Surgical Oncology, vol. 16, no. 2, pp. 352–360, 2009.

[65] Y. Du, S. M. Yan, W. Y. Gu et al., “Decreased expression of FADS1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma.” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 12, pp. 5089–5094, 2015.

[66] X. P. Wang, X. H. Li, L. Zhang et al., “High level of serum apolipoprotein A-1 is a favorable prognostic factor for overall survival in esophageal squamous cell carcinoma,” BMC Cancer, vol. 16, no. 1, p. 516, 2016.

[67] M. Li, C. Li, P. Lu et al., “Expression and function analysis of CRABP2 and FABP5, and their ratio in esophageal squamous cell carcinoma,” Open Medicine, vol. 16, pp. 1444–1456, 2021.

[68] L. Chen, Y. Duan, H. Wei et al., “Acetyl-coa carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC 1/2 inhibitors,” Expert Opinion on Investigational Drugs, vol. 28, no. 10, pp. 917–930, 2019.

[69] D. X. Luo, D. J. Tong, S. Rajput et al., “Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential,” Recent Patents on Anti-Cancer Drug Discovery, vol. 7, no. 2, pp. 168–184, 2012.

[70] H. Deng, T. Zhou, X. Mo, C. Liu, and Y. Yin, “Low-density lipoprotein promotes lymphatic metastasis of esophageal squamous cell carcinoma and is an adverse prognostic factor,” Oncology Letters, vol. 17, no. 1, pp. 1053–1061, 2019.

[71] Z. Huang, M. Zhang, A. A. Plec et al., “ACSS2 promotes systemic fat storage and utilization through selective regulation of genes involved in lipid metabolism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 115, Article ID E9499, 2018.

[72] R. W. Sabnis, “Amide-substituted condensed pyridine derivatives as ACSS2 inhibitors for treating cancer,” ACS Medicinal Chemistry Letters, vol. 12, no. 12, pp. 1870-1871, 2021.

[73] R. W. Sabnis, “Novel substituted tetrazoles as ACSS2 inhibitors for treating cancer,” ACS Medicinal Chemistry Letters, vol. 12, no. 12, pp. 1894-1895, 2021.

[74] D. Cao, S. Rajput, K. Watabe, D. F. Liao, and D. Cao, “Acetyl-CoA carboxylase-A as a novel target for cancer therapy,” Frontiers in Bioscience, vol. 52, pp. 82–26, 2010.

[75] Q. Qiu, F. Zeng, X. Liu, Q. J. Wang, and F. Deng, “Fatty acid oxidation and lymphatic palmitoyltransferase I: emerging therapeutic targets in cancer,” Cell Death & Disease, vol. 7, no. 5, p. e2226, 2016.

[76] L. J. Sharpe and A. J. Brown, “Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR),” Journal of Biological Chemistry, vol. 288, no. 26, pp. 18707–18715, 2013.

[77] E. F. Oliveira, D. Santos-Martins, A. M. Ribeiro et al., “HMG-CoA reductase inhibitors: an updated review of patents of novel compounds and formulations (2011–2015),” Expert Opinion on Therapeutic Patents, vol. 26, no. 11, pp. 1257–1272, 2016.

[78] L. Rodriguez Savicki, N. M. Bottasso Arias, N. Scaglia et al., “FABP1 knockdown in human enterocytes impairs proliferation and alters lipid metabolism,” Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids, vol. 1862, pp. 1587–1594, 2017.

[79] Y. T. Wang, C. H. Liu, and H. L. Zhu, “Fatty acid binding protein (FABP) inhibitors: a patent review (2012–2015),” Expert Opinion on Therapeutic Patents, vol. 26, no. 7, pp. 767–776, 2016.

[80] M. Ogura, “PCSK9 inhibition in the management of familial hypercholesterolemia,” Journal of Cardiology, vol. 71, no. 1, pp. 1–7, 2018.

[81] H. Orita, J. Coulter, E. Tully et al., “High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy,” Cancer Biology & Therapy, vol. 10, no. 6, pp. 549–554, 2010.

[82] C. M. Huang, C. S. Huang, T. N. Hsu et al., “Disruption of cancer metabolic SREBP1/miR-142-5p suppresses epithelial-mesenchymal transition and stemness in esophageal carcinoma,” Cells, vol. 9, no. 7, p. 1 page, 2019.

[83] L. Wang, K. Li, X. Lin et al., “Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis,” Cancer Letters, vol. 450, pp. 22–31, 2019.

[84] F. Liang, Y. G. Wang, and C. Wang, “Metformin inhibited growth, invasion and metastasis of esophageal squamous carcinoma in vitro and in vivo,” Cellular Physiology and Biochemistry, vol. 51, no. 3, pp. 1276–1286, 2018.

[85] C. Mynhardt, L. H. Damelin, R. Jivan et al., “Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma,” Journal of Cellular Biochemistry, vol. 119, no. 1, pp. 1193–1203, 2018.

[86] F. Wang, X. Ding, T. Wang et al., “Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin,” PLoS One, vol. 12, no. 4, Article ID e0174276, 2017.

[87] Z. Chen, Y. Liu, B. Qi et al., “MicroRNA-212 facilitates the motility and invasiveness of esophageal squamous carcinoma cells,” Molecular Medicine Reports, vol. 20, no. 4, pp. 3633–3641, 2019.

[88] Z. Zou, W. Zheng, H. Fan et al., “Aspirin enhances the therapeutic efficacy of cisplatin in oesophageal squamous cell carcinoma by inhibition of putative cancer stem cells,” British Journal of Cancer, vol. 125, no. 6, pp. 826–838, 2021.

[89] S. E. Choi, K. E. Perzan, A. C. Tramontano, C. Y. Kong, and C. Hur, “Statins and aspirin for chemoprevention in Barrett’s esophagus: results of a cost-effectiveness analysis,” Cancer Prevention Research, vol. 7, no. 3, pp. 341–350, 2014.

[90] T. Thomas, Y. Luke, and I. L. P. Beales, “Systematic review and meta-analysis: use of statins is associated with a reduced incidence of oesophageal adenocarcinoma,” Journal of Gastrointestinal Cancer, vol. 49, no. 4, pp. 442–454, 2018.

[91] Q. Yuan, C. D. Dong, Y. Ge et al., “Proteome and phosphoproteome reveal mechanisms of action of atorvastatin against esophageal squamous cell carcinoma,” Aging (Albany NY), vol. 11, no. 21, pp. 9530–9543, 2019.

[92] D. Sun, Q. Chen, Z. Gai et al., “The role of the carnitine/organic cation transporter novel 2 in the clinical outcome of patients with locally advanced esophageal carcinoma treated with oxaliplatin,” Frontiers in Pharmacology, vol. 12, Article ID 684545, 2021.

[93] M. Nosrati-Oskouie, N. S. Aghili-Moghaddam, T. Sathyapalan, and A. Sahebkar, “Impact of curcumin on fatty acid metabolism,” Phytotherapy Research, vol. 35, no. 9, pp. 4748–4762, 2021.

[94] D. Subramaniam, S. Punnurangam, P. Ramamoorthy et al., “Curcumin induces cell death in esophageal cancer cells through modulating notch signaling,” PLoS One, vol. 7, no. 2, Article ID e30590, 2012.

[95] O. A. Sukocheva, C. Wee, A. Ansar, D. J. Hussey, and D. I. Watson, “Effect of estrogens on growth and apoptosis in
esophageal adenocarcinoma cells,” *Diseases of the Esophagus*, vol. 26, no. 6, pp. 628–635, 2013.

[96] X. Wang, H. Guo, W. Liu et al., “Effects of siRNA-mediated knockdown of HDAC1 on the biological behavior of esophageal carcinoma cell lines,” *Medical Science Monitor*, vol. 22, pp. 1291–1296, 2016.

[97] H. Sun, L. Li, W. Li et al., “P53 transcriptionally regulates SQLE to repress cholesterol synthesis and tumor growth,” *EMBO Reports*, vol. 22, no. 10, Article ID e52537, 2021.

[98] C. Cheng, F. Geng, X. Cheng, and D. Guo, “Lipid metabolism reprogramming and its potential targets in cancer,” *Cancer Communications*, vol. 38, no. 1, p. 27, 2018.

[99] W. Ye, Y. Lin, T. Bezabeh et al., “[H NMR-based metabolomics of paired esophageal tumor tissues and serum samples identifies specific serum biomarkers for esophageal cancer,” *NMR in Biomedicine*, vol. 34, no. 6, Article ID e4505, 2021.

[100] J. D. Chow, R. T. Lawrence, M. E. Healy et al., “Genetic inhibition of hepatic acetyl-coa carboxylase activity increases liver fat and alters global protein acetylation,” *Molecular Metabolism*, vol. 3, no. 4, pp. 419–431, 2014.

[101] M. Maan, J. M. Peters, M. Dutta, and A. D. Patterson, “Lipid metabolism and lipophagy in cancer,” *Biochemical and Biophysical Research Communications*, vol. 504, no. 3, pp. 582–589, 2018.

[102] X. Luo, C. Cheng, Z. Tan et al., “Emerging roles of lipid metabolism in cancer metastasis,” *Molecular Cancer*, vol. 16, no. 1, p. 76, 2017.

[103] W. C. Man, M. Miyazaki, K. Chu, and J. Ntambi, “Colocalization of Scd1 and DGAT2: implying preference for endogenous monounsaturated fatty acids in triglyceride synthesis,” *Journal of Lipid Research*, vol. 47, no. 9, pp. 1928–1939, 2006.

[104] S. Guo, Y. Wang, D. Zhou, and Z. Li, “Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging,” *Scientific Reports*, vol. 4, no. 1, p. 5959, 2014.

[105] D. Mauvoisin, M. Prévost, S. Ducheix, M. P. Arnaud, and C. Mountier, “Key role of the ERK1/2 MAPK pathway in the transcriptional regulation of the stearoyl-CoA desaturase (Scd1) gene expression in response to leptin,” *Molecular and Cellular Endocrinology*, vol. 319, no. 1-2, pp. 116–128, 2010.

[106] C. Zhang, M. Skamagki, Z. Liu et al., “Biological significance of the suppression of oxidative phosphorylation in induced pluripotent stem cells,” *Cell Reports*, vol. 21, no. 8, pp. 2058–2065, 2017.

[107] J. Zhang, F. Song, X. Zhao et al., “EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of Scd1 in lung cancer,” *Molecular Cancer*, vol. 16, no. 1, p. 127, 2017.

[108] W. Y. Kim, “Energetic targeting of lipid synthesis in squamous cancer,” *Nature Communications*, vol. 12, no. 1, p. 4362, 2021.

[109] F. Iannelli, R. Lombardi, M. R. Milone et al., “Targeting de novo lipogenesis pathway in cancer treatment: repurposing of statins,” *Recent Patents on Anti-Cancer Drug Discovery*, vol. 13, no. 2, pp. 184–200, 2018.

[110] T. Nguyen, A. Khan, Y. Liu, H. B. El-Serag, and A. P. Thrift, “The association between statin use after diagnosis and mortality risk in patients with esophageal cancer: a retrospective cohort study of United States veterans,” *American Journal of Gastroenterology*, vol. 113, no. 9, p. 1310, 2018.

[111] H. Y. Deng, X. Lan, X. Zheng et al., “The association between statin use and survival of esophageal cancer patients: a systematic review and meta-analysis,” *Medicine (Baltimore)*, vol. 98, Article ID e16480, 29 pages, 2019.

[112] J. Shi, J. Zhu, H. Zhao, C. Zhong, Z. Xu, and F. Yao, “Squalene pathway is a therapeutic target in esophageal squamous cell carcinoma,” *Tumor Biology*, vol. 34, no. 4, pp. 429–435, 2013.

[113] M. R. Sadaria, A. E. Reppert, J. A. Yu et al., “Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells,” *The Journal of Thoracic and Cardiovascular Surgery*, vol. 142, no. 5, pp. 1152–1160, 2011.

[114] O. O. Ogunwobi and I. L. P. Beales, “Statins inhibit proliferation and induce apoptosis in Barrett’s esophageal adenocarcinoma cells,” *American Journal of Gastroenterology*, vol. 103, no. 4, pp. 825–837, 2008.

[115] Y. Jin, K. Xu, Q. Chen et al., “Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-P13K/akt pathway,” *Experimental Cell Research*, vol. 362, no. 2, pp. 362–369, 2018.

[116] M. Shyamsunder, D. F. McAuley, M. O. Shields et al., “Effect of simvastatin on physiological and biological outcomes in patients undergoing esophagectomy: a randomized placebo-controlled trial,” *Annals of Surgery*, vol. 259, no. 1, pp. 26–31, 2014.

[117] R. Fong Soe Khioe, C. Skedgel, A. Hart, M. P. N. Lewis, and L. Alexandre, “Adjuvant statin therapy for esophageal adenocarcinoma: a cost-utility analysis,” *PharmacoEconomics*, vol. 36, no. 3, pp. 349–358, 2018.

[118] F. Kastelein, K. Biermann, E. W. Steyerberg et al., “Value of A-methylacyl-CoA racemase immunohistochemistry for predicting neoplastic progression in Barrett’s oesophagus,” *Histopathology*, vol. 63, no. 5, pp. 630–639, 2013.

[119] I. Sonoda, I. Imoto, J. Inoue et al., “Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma,” *Cancer Research*, vol. 64, no. 11, pp. 3741–3747, 2004.

[120] P. Chen, L. Han, C. Wang et al., “Preoperative serum lipids as prognostic predictors in esophageal squamous cell carcinoma patients with esophagectomy,” *Oncotarget*, vol. 8, no. 25, pp. 41605–41619, 2017.

[121] H. Guan, J. Liu, P. Lv, L. Zhou, J. Zhang, and W. Cao, “MiR-305-590 inhibits migration, invasion and epithelial-to-mesenchymal transition of esophageal squamous cell carcinoma by targeting low-density lipoprotein receptor-related protein 6,” *Oncology Reports*, vol. 44, no. 4, pp. 1385–1392, 2020.
[125] Q. Liu, Q. Luo, A. Halim, and G. Song, “Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer,” Cancer Letters, vol. 401, pp. 39–45, 2017.
[126] S. Klein and R. R. Wolfe, “Whole-body lipolysis and triglyceride-fatty acid cycling in cachectic patients with esophageal cancer,” Journal of Clinical Investigation, vol. 86, no. 5, pp. 1403–1408, 1990.
[127] K. M. Nieman, I. L. Romero, B. Van Houten, and E. Lengyel, “Adipose tissue and adipocytes support tumorigenesis and metastasis,” Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids, vol. 1831, pp. 1533–1541, 2013.
[128] C. Attané and C. Muller, “Drilling for oil: tumor-surrounding adipocytes fueling cancer,” Trends in Cancer, vol. 6, no. 7, pp. 593–604, 2020.
[129] H. Bo, M. Ghazizadeh, H. Shimizu et al., “Effect of ionizing irradiation on human esophageal cancer cell lines by CDNA microarray gene expression analysis,” Journal of Nippon Medical School, vol. 71, no. 3, pp. 172–180, 2004.
[130] Y. Jin, P. J. McBie, S. L. Banman, C. Brandt, and S. J. Stone, “Diaelglycerol acyltransferase-2 (DGAT2) and monaclylycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis,” Journal of Biological Chemistry, vol. 289, no. 41, pp. 28237–28248, 2014.
[131] X. Ding, W. Zhang, S. Li, and H. Yang, “The role of cholesterol metabolism in cancer,” American Journal of Cancer Research, vol. 9, no. 2, pp. 219–227, 2019.
[132] M. Codini, M. Garcia-Gil, and E. Albi, “Cholesterol and steatois in hepatic steatosis in diabetic mice,” Journal of Cellular and Molecular Medicine, vol. 23, no. 5, pp. 3616–3628, 2019.
[133] L. Song, H. Gong, C. Lin et al., “Downregulation of mir-138 sustains NF-κB activation and promotes lipid raft formation in esophageal squamous cell carcinoma,” Clinical Cancer Research, vol. 19, no. 5, pp. 1083–1093, 2013.
[134] M. L. Lin, Y. C. Lu, H. Y. Chen, C. C. Lee, J. G. Chung, and S. S. Chen, “Suppressing the formation of lipid raft-associated RAC1/P13K/AKT signaling complexes by curcumin inhibits SDF-1α-induced invasion of human esophageal carcinoma cells,” Molecular Carcinogenesis, vol. 53, no. 5, pp. 360–379, 2014.
[135] L. Song, H. Gong, C. Lin et al., “Flotillin-1 promotes tumor necrosis factor-α receptor signaling and activation of NF-κB in esophageal squamous cell carcinoma cells,” Gastroenterology, vol. 143, no. 4, pp. 995–1005, 2012.
[136] H. F. Turk and R. S. Chapkin, “Membrane lipid raft organization is uniquely modified by N-3 polyunsaturated fatty acids,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 88, no. 1, pp. 43–47, 2013.
[137] S. Dambal, M. Alfaqih, S. Sanders et al., “27-hydroxycholesterol impairs plasma membrane lipid raft signaling as evidenced by inhibition of IL6-JAK-STAT3 signaling in prostate cancer cells,” Molecular Cancer Research, vol. 18, no. 5, pp. 671–684, 2020.
[138] J. Molendijk, T. M. T. Nguyen, I. Brown et al., “Chronic high-fat diet induces early Barrett’s esophagus in mice through lipidome remodeling,” Biomolecules, vol. 10, p. 776, 2020.
[139] J. Fang, L. Chu, C. Li et al., “Jak2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway,” Oncology Reports, vol. 33, no. 1, pp. 494–502, 2015.
[140] X. Huo, X. Zhang, C. Yu et al., “Aspirin prevents NF-κB activation and CDX2 expression stimulated by acid and bile salts in esophageal squamous cells of patients with Barrett’s oesophagus,” Gut, vol. 67, no. 4, pp. 606–615, 2018.
[141] J. Cai, X. Qian, C. Tan et al., “Esophageal cancer stem cells and implications for future therapeutics,” Oncotargets and Therapy, vol. 9, pp. 2247–2254, 2016.
[142] C. Zhou, N. Fan, F. Liu et al., “Linking cancer stem cell plasticity to therapeutic resistance-mechanism and novel therapeutic strategies in esophageal cancer,” Cells, vol. 9, p. 1481, 2020.
[143] D. Yan, Q. Yang, M. Shi et al., “Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway,” European Journal of Immunology, vol. 43, no. 11, pp. 2943–2955, 2013.
[144] H. Li, Q. Yao, L. Min et al., “The combination of two bioactive constituents, lactoferrin and linoleic acid, inhibits mouse xenograft esophageal tumor growth by down-regulating lischomolyltaurine and inhibiting the JAK2/STAT3-related pathway,” ACS Omega, vol. 5, no. 33, pp. 20755–20764, 2020.
[145] T. Maehama, M. Nishio, J. Otani, T. W. Mak, and A. Suzuki, “The role of hippo-YAP signaling in squamous cell carcinomas,” Cancer Science, vol. 112, pp. 51–60, 2021.
[146] Z. Sha, Y. Gao, G. Zhang et al., “A functional interaction between hippo-yap signalling and srebps mediates hepatic steatosis in diabetic mice,” Journal of Cellular and Molecular Medicine, vol. 23, no. 5, pp. 3616–3628, 2019.
[147] S. Zhao, J. Zhao, X. Li et al., “Effect of YAP1 silencing on esophageal cancer,” Oncotargets and Therapy, vol. 9, pp. 3137–3146, 2016.
[148] G. Sorrentino, N. Ruggeri, V. Specchia et al., “Metabolic control of YAP and TAZ by the mevalonate pathway,” Nature Cell Biology, vol. 16, no. 4, pp. 357–366, 2014.
[149] X. Zhang, H. Zhao, Y. Li et al., “The role of YAP/TAZ activity in cancer metabolic reprogramming,” Molecular Cancer, vol. 17, pp. 134–1, 2018.
[150] Y. Zheng, Z. Chen, Y. Han et al., “Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment,” Nature Communications, vol. 11, no. 1, p. 6268, 2020.
[151] M. E. Kavanagh, M. J. Conroy, N. E. Clarke et al., “Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma,” Cancer Letters, vol. 370, pp. 117–124, 2016.
[152] V. A. Gerrits, R. J. Kishon, M. O. Johnson et al., “Foxp3 and toll-like receptor signaling balance Treg cell anabolic metabolism for suppression,” Nature Immunology, vol. 17, no. 12, pp. 1459–1466, 2016.
[153] C. Liu, M. Chikina, R. Deshpande et al., “Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8+ T cell-derived interferon,” Immunity, vol. 51, no. 2, pp. 381–397, 2019.
[154] L. Z. Shi, R. Wang, G. Huang et al., “HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells,” Journal of Experimental Medicine, vol. 208, no. 7, pp. 1367–1376, 2011.
[155] K. S. Smigiel, S. Srivastava, J. M. Stolley, and D. J. Campbell, “Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation,” Immunological Reviews, vol. 259, no. 1, pp. 40–59, 2014.
[156] T. Kitamura, B. Z. Qian, and J. W. Pollard, “Immune cell promotion of metastasis,” Nature Reviews Immunology, vol. 15, no. 2, pp. 73–86, 2015.
[157] X. Yuan, Y. Li, A. Z. Zhang et al., “Tumor-associated macrophage polarization promotes the progression of esophageal carcinoma,” Aging (Albany NY), vol. 13, no. 2, pp. 2049–2072, 2020.

[158] J. Zhou, S. Zheng, T. Liu et al., “MCP2 activates NF-κB signaling pathway promoting the migration and invasion of ESCC cells,” Cell Biology International, vol. 42, no. 3, pp. 365–372, 2018.

[159] J. Y. Liu, E. Li, L. P. Wang et al., “CTLA-4 vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma,” British Journal of Cancer, vol. 113, no. 5, pp. 747–755, 2015.

[160] A. Tanaka and S. Sakaguchi, “Regulatory T cells in cancer immunotherapy,” Cell Research, vol. 27, no. 1, pp. 109–118, 2017.

[161] N. Patsoukis, K. Bardhan, P. Chatterjee et al., “PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation,” Nature Communications, vol. 6, no. 1, p. 6692, 2015.

[162] Y. Gokon, F. Fujishima, Y. Taniyama et al., “Immune microenvironment in Barrett’s esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression,” Virchows Archiv, vol. 477, no. 6, pp. 825–834, 2020.

[163] Y. Xiang and H. Miao, “Lipid metabolism in tumor-associated macrophages,” Advances in Experimental Medicine and Biology, vol. 1316, pp. 87–101, 2021.

[164] C. H. Jiang, W. H. Liang, F. P. Li et al., “Distribution and prognostic impact of M1 macrophage on esophageal squamous cell carcinoma,” Carcinogenesis, vol. 42, no. 4, pp. 537–545, 2021.

[165] M. Xu, X. Wang, Y. Li et al., “Arachidonic acid metabolism controls macrophage alternative activation through regulating oxidative phosphorylation in PPARγ dependent manner,” Frontiers in Immunology, vol. 12, Article ID 618501, 2021.

[166] A. Batista-Gonzalez, R. Vidal, A. Criollo, and L. J. Carreño, “New insights on the role of lipid metabolism in the metabolic reprogramming of macrophages,” Frontiers in Immunology, vol. 10, p. 2993, 2019.

[167] J. Yao, L. Duan, X. Huang et al., “Development and validation of a prognostic gene signature correlated with M2 macrophage infiltration in esophageal squamous cell carcinoma,” Frontiers in Oncology, vol. 11, Article ID 769727, 2021.

[168] J. Zhou, S. Zheng, T. Liu et al., “Infiltrated M2 tumour-associated macrophages in the stroma promote metastasis and poor survival in oesophageal squamous cell carcinoma,” Histology & Histopathology, vol. 34, no. 5, pp. 563–572, 2019.

[169] W. Yang and J. Yu, “Immunologic function of dendritic cells in esophageal cancer,” Digestive Diseases and Sciences, vol. 53, no. 7, pp. 1739–1746, 2008.

[170] S. R. Chen, Y. P. Luo, J. K. Zhang et al., “Study on immune function of dendritic cells in patients with esophageal carcinoma,” World Journal of Gastroenterology, vol. 10, no. 7, pp. 934–939, 2004.

[171] M. Ikeguchi, M. Ikeda, S. Tatebe, M. Maeta, and N. Kaibara, “Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma,” Oncology Reports, vol. 5, no. 5, pp. 1185–1189, 1998.

[172] S. Brix, P. Lund, T. M. R. Kjær, E. M. Straarup, L. I. Hellgren, and H. Frokiaer, “Cd4+ T-cell activation is differentially modulated by bacteria-primed dendritic cells, but is generally down-regulated by N-3 polyunsaturated fatty acids,” Immunology, vol. 129, no. 3, pp. 338–350, 2010.

[173] Y. V. Bobryshev, D. Tran, M. C. Killingsworth, M. Buckland, and R. V. N. Lord, “Dendritic cells in Barrett’s esophagus and esophageal adenocarcinoma,” Journal of Gastrointestinal Surgery, vol. 13, no. 1, pp. 44–53, 2009.

[174] Q. Zhao, L. Huang, G. Qin et al., “Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IFN-γ/IL-1β-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma,” Cancer Letters, vol. 518, pp. 35–48, 2021.

[175] W. Wang, R. Wang, Z. Zhang, D. Li, and Y. Yu, “Enhanced PPAR-gamma expression may correlate with the development of Barrett’s esophagus and esophageal adenocarcinoma,” OncoResearch Featuring Preclinical and Clinical Cancer Therapeutics, vol. 19, no. 3, pp. 141–147, 2011.

[176] D. A. Chistiakov, A. N. Orekhov, and Y. V. Bobryshev, “Dendritic cells in esophageal adenocarcinoma: the currently available information and possibilities to use dendritic cells for immunotherapeutic approaches,” Current Pharmaceutical Design, vol. 22, no. 3, pp. 307–311, 2016.

[177] J. Zhou, S. Zheng, T. Liu et al., “MCP2 activates NF-κB and H. Frøkiaer, “Cytotoxic T-cell activation is differentially modulated by bacteria-primed dendritic cells, but is generally down-regulated by N-3 polyunsaturated fatty acids,” Immunology, vol. 129, no. 3, pp. 338–350, 2010.”

[178] O. Lyros, L. Nie, T. Moore et al., “Dysregulation of Wnt5a/RO2 signaling characterizes the progression of Barrett-associated esophageal adenocarcinoma,” Molecular Cancer Research, vol. 14, no. 7, pp. 647–659, 2016.

[179] W. Wang, R. Wang, Z. Zhang, D. Li, and Y. Yu, “Enhanced PPAR-gamma expression may correlate with the development of Barrett’s esophagus and esophageal adenocarcinoma,” OncoResearch Featuring Preclinical and Clinical Cancer Therapeutics, vol. 19, no. 3, pp. 141–147, 2011.

[180] F. Hossain, A. A. Al-Khami, D. Wyczewchowska et al., “Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies,” Cancer Immunology Research, vol. 3, no. 11, pp. 1236–1247, 2015.

[181] A. A. Al-Khami, L. Zheng, L. Del Valle et al., “Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells,” OncoImmunology, vol. 6, no. 10, Article e1344804, 2017.

[182] J. Liu, Y. Wang, L. F. Zuo, F. L. Li, Y. Wang, and J. L. Liu, “Expression and clinical significance of COX-2, P-STAT3, P-STAT5 and P-STAT5 in esophageal carcinoma,” Ai Zheng, vol. 26, no. 5, pp. 458–462, 2007.

[183] H. Huang, G. Zhang, G. Li, H. Ma, and X. Zhang, “Circulating CD14+HLA-DR−/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC,” Tumor Biology, vol. 36, no. 10, pp. 7987–7996, 2015.

[184] A. O. Adeshakin, W. Liu, F. O. Adeshakin et al., “Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy,” Cellular Immunology, vol. 362, Article ID 104286, 2021.

[185] S. Paul and G. Lal, “The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy,” Frontiers in Immunology, vol. 8, p. 1124, 2017.

[186] J. Wang, X. Jin, J. Liu et al., “The prognostic value of B7-H6 protein expression in human oral squamous cell carcinoma,” Journal of Oral Pathology & Medicine, vol. 46, no. 9, pp. 766–772, 2017.
[187] L. Lv, K. Pan, X. D. Li et al., “The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma,” PLoS One, vol. 6, no. 3, Article ID e18219, 2011.

[188] F. Quilty, M. Freeley, S. Gargan, J. Gilmer, and A. Long, “Deoxycholic acid induces proinflammatory cytokine production by model esophageal cells via lipid rafts,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 214, Article ID 105987, 2021.

[189] J. Wu, F. X. Gao, C. Wang et al., “IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in esophageal squamous cell carcinoma,” Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 321, 2019.

[190] R. P. Donnelly, R. M. Loftus, S. E. Keating et al., “MTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function,” The Journal of Immunology, vol. 193, no. 9, pp. 4477–4484, 2014.

[191] N. Assmann, K. L. O’Brien, R. P. Donnelly et al., “SREBP-controlled glucose metabolism is essential for NK cell functional responses,” Nature Immunology, vol. 18, no. 11, pp. 1197–1206, 2017.

[192] P. Yaqoob, E. A. Newsholme, and P. C. Calder, “Inhibition of natural killer cell activity by dietary lipids,” Immunology Letters, vol. 41, no. 2-3, pp. 241–247, 1994.

[193] L. M. Tobin, M. Mavinkurve, E. Carolan et al., “NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient,” JCI Insight, vol. 2, Article ID 94939, 2017.

[194] S. Viel, L. Besson, E. Charrier et al., “Alteration of natural killer cell phenotype and function in obese individuals,” Clinical Immunology, vol. 177, pp. 12–17, 2017.

[195] Y. Yu, C. H. Xiao, L. D. Tan, Q. S. Wang, X. Q. Li, and Y. M. Feng, “Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-B signalling,” British Journal of Cancer, vol. 110, no. 3, pp. 724–732, 2014.

[196] Y. Qiao, C. Zhang, A. Li et al., “IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma,” Oncogene, vol. 37, no. 7, pp. 873–883, 2018.

[197] B. Dirat, L. Bochet, M. Dabek et al., “Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion,” Cancer Research, vol. 71, pp. 2455–2465, 2011.

[198] K. Fujisaki, H. Fujimoto, T. Sangai et al., “Cancer-mediated adipose reversion promotes cancer cell migration via IL-6 and MCP-1,” Breast Cancer Research and Treatment, vol. 150, no. 2, pp. 255–263, 2015.

[199] M. Petruzzelli, M. Schweiger, R. Schreiber et al., “A switch from white to Brown fat increases energy expenditure in cancer-associated cachexia,” Cell Metabolism, vol. 20, no. 3, pp. 433–447, 2014.

[200] S. Wueest and D. Konrad, “The role of adipocyte-specific IL-6-type cytokine signaling in FFA and leptin release,” Adipocyte, vol. 7, no. 3, pp. 226–228, 2018.

[201] U. Rozovski, D. M. Harris, P. Li et al., “STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells,” Oncotarget, vol. 9, pp. 21268–21280, 2018.